Definitive Healthcare (DH) 10-Q4 Aug 222022 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 02, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	Definitive Healthcare Corp.
Entity Central Index Key	0001861795
Entity Tax Identification Number	86-3988281
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-40815
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	550 Cochituate Road
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	508
Local Phone Number	720-4224
Trading Symbol	DH
Title of 12(b) Security	Class A Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock Shares Outstanding		100,511,143

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 228,202	$ 387,498
Short-term investments	118,216
Accounts receivable, net	31,734	43,336
Prepaid expenses and other current assets	9,591	6,518
Current portion of deferred contract costs	8,469	6,880
Total current assets	396,212	444,232
Property and equipment, net	4,760	5,069
Operating lease right-of-use assets	10,552	0
Other assets	3,243	8,431
Deferred contract costs, net of current portion	12,933	11,667
Investment in equity securities	0	32,675
Intangible assets, net	372,196	352,470
Goodwill	1,322,959	1,261,444
Total assets	2,122,855	2,115,988
Current liabilities:
Accounts payable	6,692	4,651
Accrued expenses and other current liabilities	14,682	22,658
Current portion of deferred revenue	88,714	83,611
Current portion of term loan	6,875	6,875
Operating lease liabilities current	2,225	0
Total current liabilities	119,188	117,795
Long term liabilities:
Deferred revenue	278	412
Term loan, net of current portion	260,646	263,808
Operating lease liabilities, net of current portion	10,596
Tax receivable agreements liability	155,900	153,529
Deferred tax liabilities	85,596	75,888
Other long-term liabilities	1,951	1,294
Total liabilities	634,155	612,726
Equity:
Additional paid-in capital	929,842	890,724
Accumulated other comprehensive income	1,994	62
Accumulated deficit	(31,451)	(17,677)
Noncontrolling interests	588,215	630,056
Total equity	1,488,700	1,503,262
Total liabilities and equity	2,122,855	2,115,988
Common Class A
Equity:
Common stock, value	100	97
Common Class B
Equity:
Common stock, value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common Class A
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	100,484,715	97,030,095
Common stock, shares outstanding	100,484,715	97,030,095
Common Class B
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	54,745,380	58,244,627
Common stock, shares outstanding	52,196,192	55,488,221

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue		$ 54,548	$ 39,821	$ 104,672	$ 76,757
Cost of revenue:
Cost of revenue exclusive of amortization		6,198	4,570	12,148	8,766
Amortization		5,580	5,299	10,958	10,540
Gross profit		42,770	29,952	81,566	57,451
Operating expenses:
Sales and marketing		23,585	12,884	44,878	24,627
Product development		8,706	4,277	15,556	8,071
General and administrative		9,392	6,375	19,846	11,011
Depreciation and amortization		10,194	9,608	20,068	19,054
Transaction and restructuring expenses		2,107	3,431	3,417	3,469
Total operating expenses		53,984	36,575	103,765	66,232
Loss from operations		(11,214)	(6,623)	(22,199)	(8,781)
Other expense, net:
Other income (expense),net		4,002	(100)	3,901	24
Interest expense, net		(2,580)	(8,316)	(4,464)	(16,770)
Total other income (expense), net		1,422	(8,416)	(563)	(16,746)
Net loss before income taxes		(9,792)	(15,039)	(22,762)	(25,527)
Income tax benefit		213	0	126	0
Net loss		(9,579)	(15,039)	(22,636)	(25,527)
Less: Net loss attributable to Definitive OpCo prior to the Reorganization Transactions		0	(15,039)	0	(25,527)
Less: Net loss attributable to noncontrolling interests		(4,429)	0	(8,862)	0
Net loss attributable to Definitive Healthcare Corp.		$ (5,150)	$ 0	$ (13,774)	$ 0
Net loss per share of Class A common stock:
Basic and diluted	[1]	$ (0.05)		$ (0.14)
Basic and diluted	[1]	$ (0.05)		$ (0.14)
Weighted average Class A Common Stock outstanding:
Basic and diluted	[1]	99,203,697		98,186,909
Basic and diluted	[1]	99,203,697		98,186,909

[1] (1) Basic and diluted net loss per share of Class A Common Stock is applicable only for the periods beginning from September 15, 2021, which is the period following the IPO and related Reorganization Transactions. See Note 19 for the number of shares used in the computation of net loss per share of Class A Common Stock and the basis for the computation of net loss per share.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (9,579)	$ (15,039)	$ (22,636)	$ (25,527)
Other comprehensive loss:
Foreign currency translation adjustments	105	(19)	111	144
Unrealized loss on available-for-sale securities	(143)	0	(452)	0
Unrealized gain on interest rate hedging instruments	1,694	0	3,340	0
Comprehensive loss	(7,923)	(15,058)	(19,637)	(25,383)
Less: Comprehensive loss attributable to Definitive OpCo prior to the Reorganization Transactions	0	(15,058)		(25,383)
Less: Comprehensive loss attributable to noncontrolling interests	(3,849)	0	(7,795)	0
Comprehensive loss attributable to Definitive Healthcare Corp.	$ (4,074)	$ 0	$ (11,842)	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY AND TOTAL EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Reorganization Transactions [Member]	Class A Units	Class B Units	Members Equity	Members Equity Reorganization Transactions [Member]	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 1,195,563				$ 1,195,694				$ (131)
Net loss prior to Reorganization Transactions		$ (10,488)				$ (10,488)
Other comprehensive income	163								163
Equity-based compensation	406				406
Ending Balance at Mar. 31, 2021	1,185,644				1,185,612				32
Beginning Balance at Dec. 31, 2020	1,195,563				1,195,694				(131)
Net loss	(25,527)
Net loss	0
Net loss prior to Reorganization Transactions	(25,383)
Ending Balance at Jun. 30, 2021	1,174,373				1,174,360				13
Beginning Balance at Mar. 31, 2021	1,185,644				1,185,612				32
Net loss	(15,039)
Net loss	0
Net loss prior to Reorganization Transactions	(15,058)	$ (15,039)				$ (15,039)
Other comprehensive income	(19)								(19)
Equity-based compensation	1,615				1,615
Distributions to members prior to Reorganization Transactions	(3,328)				(3,328)
Members' contributions	5,500				5,500
Ending Balance at Jun. 30, 2021	1,174,373				$ 1,174,360				13
Beginning Balance at Dec. 31, 2021	1,503,262		$ 97				$ 890,724	$ (17,677)	62	$ 630,056
Beginning Balance (in shares) at Dec. 31, 2021			97,030,095	58,244,627
Net loss	(13,057)
Net loss								(8,624)		(4,433)
Other comprehensive income	1,343								856	487
Effect of LLC unit exchanges	(897)		$ 1				5,080			(5,978)
Effect of LLC unit exchanges, shares			544,302	(544,302)
Equity-based compensation	6,872						4,377			2,495
Distributions to noncontrolling interests	(258)									(258)
Forfeited unvested incentive units				(33,549)
Vested incentive units							(696)			696
Ending Balance at Mar. 31, 2022	1,497,265		$ 98	$ 0			899,485	(26,301)	918	623,065
Ending Balance (in shares) at Mar. 31, 2022			97,574,397	57,666,776
Beginning Balance at Dec. 31, 2021	1,503,262		$ 97				890,724	(17,677)	62	630,056
Beginning Balance (in shares) at Dec. 31, 2021			97,030,095	58,244,627
Net loss	(22,636)
Net loss	(13,774)
Ending Balance at Jun. 30, 2022	1,488,700		$ 100	$ 0			929,842	(31,451)	1,994	588,215
Ending Balance (in shares) at Jun. 30, 2022			100,484,715	54,745,380
Beginning Balance at Mar. 31, 2022	1,497,265		$ 98	$ 0			899,485	(26,301)	918	623,065
Beginning Balance (in shares) at Mar. 31, 2022			97,574,397	57,666,776
Net loss	(9,579)
Net loss	(5,150)							(5,150)		(4,429)
Net loss prior to Reorganization Transactions	0
Other comprehensive income	1,656								1,076	580
Effect of LLC unit exchanges	(4,618)		$ 2				24,818			(29,438)
Effect of LLC unit exchanges, shares			2,898,589	(2,898,589)
Equity-based compensation	9,005						5,852			3,153
Forfeited unvested incentive units				(22,807)
Vested incentive units							(358)			358
Issuance of Class A Common Stock upon vesting of RSUs, shares			11,729
Issuance of Class A Common Stock upon vesting of RSUs							45			(45)
Distributions to members prior to Reorganization Transactions	(5,029)									(5,029)
Ending Balance at Jun. 30, 2022	$ 1,488,700		$ 100	$ 0			$ 929,842	$ (31,451)	$ 1,994	$ 588,215
Ending Balance (in shares) at Jun. 30, 2022			100,484,715	54,745,380

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows provided by operating activities:
Net loss	$ (9,579)	$ (13,057)	$ (15,039)	$ (22,636)	$ (25,527)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization				1,252	741
Amortization of intangible assets				29,774	28,853
Amortization of deferred contract costs				3,991	1,902
Equity-based compensation				15,877	2,021
Amortization of debt issuance costs				351	1,047
Allowance for doubtful accounts				6	(105)
Non-cash restructuring charges related to office leases				1,023	0
Tax receivable agreement remeasurement				(3,143)	0
Changes In Fair Value Of Contingent Consideration				0	3,381
Deferred income taxes				(164)	0
Changes in operating assets and liabilities:
Accounts receivable				15,270	10,476
Prepaid expenses and other current assets				1,319	(614)
Deferred contract costs				(6,846)	(6,042)
Contingent consideration				(6,400)	0
Accounts payable, accrued expenses and other current liabilities				(2,238)	(2,119)
Deferred revenue				1,678	7,927
Net cash provided by operating activities				29,114	21,941
Cash flows used in investing activities:
Purchases of property, equipment, and other assets				(1,577)	(5,222)
Purchases of short-term investments				(162,957)	0
Maturities of short-term investments				(44,000)	0
Cash paid for acquisitions, net of cash acquired				(56,499)	0
Net cash used in investing activities				(177,033)	(5,222)
Cash flows used in financing activities:
Repayments of term loans				(3,438)	(2,340)
Payment of contingent consideration				(1,100)	(1,500)
Payments of equity offering issuance costs				(1,299)	(1,394)
Member contributions				0	5,500
Member distributions				(5,287)	(3,328)
Net cash used in financing activities				(11,124)	(3,062)
Net (decrease) increase in cash and cash equivalents				(159,043)	13,657
Effect of exchange rate changes on cash and cash equivalents				(253)	7
Cash and cash equivalents, beginning of period		$ 387,498		387,498	24,774	$ 24,774
Cash and cash equivalents, end of period	$ 228,202		$ 38,438	228,202	38,438	$ 387,498
Supplemental cash flow disclosures:
Interest				4,350	15,972
Income taxes				0	13
Acquisitions:
Net assets acquired, net of cash acquired				97,499	0
Initial cash investment in prior year				(40,000)
Contingent consideration				(1,000)	0
Net cash paid for acquisitions				56,499	0
Supplemental disclosure of non-cash investing activities:
Capital expenditures included in accrued expenses				3,500	0
Supplemental disclosure of non-cash financing activities
Unpaid Public Offering Costs Included In Accrued Expenses				$ 0	$ 2,426

Description of Business

Description of Business	6 Months Ended
Description of Business	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Definitive Healthcare Corp., through its operating subsidiary, Definitive OpCo, provides comprehensive and up-to-date hospital and healthcare-related information and insight across the entire healthcare continuum via a multi-tenant software-as-a-service (“SaaS”) platform which combines proprietary and public sources to deliver insights. The Company is headquartered in Framingham, MA. Organization Definitive Healthcare Corp. was formed on May 5, 2021 as a Delaware corporation to facilitate an initial public offering (“IPO”) and other related transactions to carry on the business of Definitive OpCo. Following consummation of the Reorganization Transactions, Definitive OpCo became an indirect subsidiary of Definitive Healthcare Corp. Initial Public Offering On September 17, 2021, Definitive Healthcare completed its IPO, in which it sold 17,888,888 shares of Class A Common Stock (including shares issued pursuant to the exercise in full of the underwriters’ option to purchase additional shares) at a public offering price of $ 27.00 per share for net proceeds of $ 452.8 million, after deducting underwriters’ discounts and commissions (but excluding other offering expenses and reimbursements). Definitive Healthcare used net proceeds from the IPO to (i) acquire 14,222,222 newly issued limited liability company interests (“LLC Units”) from Definitive OpCo; (ii) purchase 1,169,378 LLC Units from certain holders of LLC Units prior to the IPO; and (iii) repurchase 2,497,288 shares of Class A Common Stock received by the former shareholders of certain Blocker Companies (as defined below). Definitive OpCo used proceeds from the IPO to pay fees and expenses of approximately $ 11.4 million incurred in connection with the IPO and the Reorganization Transactions and to repay $ 199.6 million, inclusive of accrued interest expense, of the outstanding borrowings under our 2019 Credit Agreement, with the remaining proceeds intended to be used for general corporate purposes. Reorganization Transactions In connection with the IPO, the Company completed the following transactions (the “Reorganization Transactions”). Definitive OpCo entered into a second amended and restated limited liability company agreement (the “Amended LLC Agreement”) pursuant to which members of Definitive OpCo prior to the IPO who continue to hold LLC Units have the right to require Definitive OpCo to exchange all or a portion of their LLC Units for newly issued shares of Class A Common Stock. Until exchanged, each LLC Unit is coupled with one share of Definitive Healthcare Corp. Class B Common Stock. The total amount of shares of Class B Common Stock outstanding is equal to the number of vested LLC Units outstanding. Entities treated as corporations for U.S. tax purposes that held LLC Units (individually, a “Blocker Company” and collectively, the "Blocker Companies") each merged with a merger subsidiary and subsequently merged into Definitive Healthcare Corp. and are now holders of Class A Common Stock. Following the Reorganization Transactions, Definitive Healthcare Corp. became a holding company, with its sole material asset being a controlling equity interest in Definitive OpCo. Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo and reports the noncontrolling interests of unexchanged LLC Unit holders on its condensed consolidated financial statements. In connection with the Reorganization Transactions and the IPO, Definitive Healthcare Corp entered into a tax receivable agreement. See Note 18. Income Taxes . Follow-On Offering On November 22, 2021, Definitive Healthcare Corp. completed a follow-on offering, in which it sold 11,000,000 shares of Class A Common Stock at a public offering price of $ 36.00 per share for net proceeds of $ 382.1 million, after deducting underwriters’ discounts and commissions (but excluding other offering expenses and reimbursements). Definitive Healthcare Corp. used net proceeds from the follow-on offering to (i) acquire 7,000,000 newly issued LLC Units from Definitive OpCo; (ii) purchase 1,766,762 LLC Units from certain unitholders; and (iii) repurchase 2,233,238 shares of Class A Common Stock received by the former shareholders of certain Blocker Companies. Definitive OpCo used net proceeds from the follow-on offering to pay fees and expenses of approximately $ 1.6 million incurred in connection with the follow-on offering, with the remaining proceeds intended to be used for general corporate purposes.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 are unaudited. Amounts for the period from January 1, 2021 through June 30, 2021 presented in the condensed consolidated financial statements and notes to the condensed consolidated financial statements herein represent the historical operations of Definitive OpCo. The amounts as of June 30, 2022 and December 31, 2021 and for the period from January 1, 2022 through June 30, 2022 reflect the consolidated operations of Definitive Healthcare Corp. and its consolidated subsidiaries. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered necessary for a fair presentation of the unaudited interim condensed consolidated financial statements for these interim periods have been included. Refer to Note 2 below and to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 for the Company’s significant accounting policies and estimates. Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations and useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates. Leases Effective January 1, 2022, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02— Leases (Topic 842) (“ASC 842”) . In accordance with ASC 842, the Company, at the inception of the contract, determines whether a contract is or contains a lease. For leases with terms greater than 12 months, the Company records the related operating or finance right of use asset and lease liability at the present value of lease payments over the lease term. The Company is generally not able to readily determine the implicit rate in the lease and therefore uses the determined incremental borrowing rate at lease commencement to determine the present value of lease payments. The incremental borrowing rate represents an estimate of the market interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. Renewal options are not included in the measurement of the right of use assets and lease liabilities unless the Company is reasonably certain to exercise the optional renewal periods. Some leases also include early termination options, which can be exercised under specific conditions. Additionally, certain leases contain incentives, such as construction allowances from landlords. These incentives reduce the right-of-use asset related to the lease. Some of the Company's leases contain rent escalations over the lease term. The Company recognizes expense for operating leases on a straight-line basis over the lease term. The Company’s lease agreements contain variable lease payments for common area maintenance, utility, and taxes. The Company has elected the practical expedient to combine lease and non-lease components for all asset categories. Therefore, the lease payments used to measure the lease liability for these leases include fixed minimum rentals along with fixed non-lease component charges. The Company does not have significant residual value guarantees or restrictive covenants in the lease portfolio. Derivative Instruments and Hedging Activities FASB Accounting Standards Codification (“ASC”) 815— Derivatives and Hedging (“ASC 815”), provides the disclosure requirements for derivatives and hedging activities with the intent to provide users of financial statements with an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how the entity accounts for derivative instruments and related hedged items, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. Further, qualitative disclosures are required that explain the Company’s objectives and strategies for using derivatives, as well as quantitative disclosures about the fair value of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative instruments. As required by ASC 815, the Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting. In accordance with the FASB’s fair value measurement guidance in ASU 2011-04— Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (“ASC 820”), th e Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. Adoption of Recently Issued Financial Accounting Standards In October 2021, the FASB issued ASU No. 2021-08— Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This new accounting standard requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606— Revenue from Contracts with Customers . The standard requires the acquirer to recognize contract assets and contract liabilities at the same amounts recorded by the acquiree. The new accounting guidance is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this new accounting guidance effective January 1, 2022. In connection with the acquisition of Analytical Wizards completed in the first quarter of 2022, the Company recorded contract liabilities of $ 3.4 million. Refer to Note 3. Acquisitions for further details. In December 2019, the FASB issued ASU No. 2019-12— Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes. This standard removes certain exceptions for investments, intra-period allocations and interim tax calculations and adds guidance to reduce complexity in accounting for income taxes. The amendment is effective for fiscal years beginning after December 15, 2021. The Company adopted this new accounting guidance effective January 1, 2022, but the adoption did not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02— Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company adopted ASU No. 2016-02— Leases effective January 1, 2022 using the modified retrospective transition method. Prior period results will continue to be presented under ASC 840 as it was the accounting standard in effect for such periods. The Company elected to apply the package of practical expedients that allows entities to forgo reassessing at the transition date: (1) whether any expired or existing contracts are or contain leases; (2) lease classification for any expired or existing leases; and (3) whether unamortized initial direct costs for existing leases meet the definition of initial direct costs under the new guidance. The Company did not elect the hindsight practical expedient. The Company elected to use the practical expedient that allows the combination of lease and non-lease contract components in all of its underlying asset categories. Finally, the Company also elected a policy of not recording leases on its condensed consolidated balance sheets when the leases have a term of 12 months or less and the Company is not reasonably certain to elect an option to renew the leased asset. Due to the adoption of this guidance, the Company recognized operating right-of-use assets of $ 12.7 million and operating lease liabilities of $ 14.0 million as of the date of adoption. The difference between the right-of-use assets and lease liabilities on the accompanying condensed consolidated balance sheet is primarily due to the accrual for lease payments as a result of straight-line lease expense and unamortized tenant incentive liability balances. The Company did not have any impact to opening retained earnings as a result of the adoption of the guidance. The adoption of this new guidance did not have a material impact on the Company’s results of operations, comprehensive loss, cash flows, liquidity or the Company’s covenant compliance under its existing credit agreement. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13 —Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments. This standard is intended to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope, such as trade receivables. The amendment is effective for fiscal years beginning after December 15, 2022. The Company will adopt the update effective January 1, 2023 and does not expect the adoption of the standard to have a material impact on its consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04— Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendments of ASU No. 2020-04 are effective for companies as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. The amendments in this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform and provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The Company is evaluating the impact that the amendments of this standard would have on its consolidated financial position or results of operations upon adoption.

Acquisitions

Acquisitions	6 Months Ended
Acquisitions	Jun. 30, 2022
Business Combinations [Abstract]
Acquisitions	3. Acquisitions On December 22, 2021, Definitive Healthcare, LLC (“DH, LLC”), an indirect wholly owned subsidiary of Definitive Healthcare Corp. made a $ 40.0 million investment in Analytical Wizards Inc. (“AW” or “Analytical Wizards”), a privately held company. Analytical Wizards automates complex analytic models using tools that expedite efficient big data mining through artificial intelligence ("A.I.") and machine learning ("M.L.") to uncover deep insights. In the transaction the Company purchased Series B Convertible Preferred Stock of AW (“Series B Preferred Stock”), representing 35 % ownership of AW, and an option to acquire the remaining 65 % ownership (the "Purchase Option") for $ 65.0 million. As of December 31, 2021, the Company determined it did not have a controlling financial interest in AW at transaction close as the Company did not have the right to control the governing body of AW or have control through other contractual rights. At December 31, 2021, because the Series B Preferred Stock and the Purchase Option did not have readily determinable fair values, the Company elected to apply the measurement alternative and adjust the carrying value of the investments in AW for impairments and observable prices in identical or similar equity securities of AW. The Company paid $ 40.0 million for the Series B Preferred Stock and Purchase Option, which was allocated on a relative fair value basis such that the Series B Preferred Stock and Purchase Option had carrying values of $ 32.7 million and $ 7.3 million at the time of the transaction, respectively. The Series B Preferred Stock was recorded in Investments in equity securities and the Purchase Option was recorded in Other assets in the accompanying condensed consolidated balance sheet as of December 31, 2021. On February 18, 2022, the Company purchased the remaining 65 % of AW’s equity for $ 65.0 million, net of cash acquired and an estimated working capital adjustment and other customary purchase price adjustments (the “AW acquisition”). The Company’s previously held investment and Purchase Option were remeasured at fair value as of the date the Purchase Option was exercised. The remeasurement had an immaterial impact on the condensed consolidated statements of operations for the three months ended March 31, 2022. The Company has included the financial results of Analytical Wizards in the condensed consolidated financial statements from February 18, 2022 , the date of acquisition. Upon the consummation of the acquisition, AW became an indirect wholly owned subsidiary of Definitive Healthcare Corp. The total consideration for the initial investment and subsequent exercise of the Purchase Option was $ 99.4 million, consisting of $ 40.0 million for the initial investment paid in December 2021, approximately $ 58.6 million of cash paid at closing, $ 0.2 million reimbursement from sellers for working capital adjustments, and up to $ 5.0 million of contingent consideration, initially valued at $ 1.0 million. The contingent consideration, which relates to earn-out payments that may be paid out, subject to meeting certain expense control metrics during the two-year period following the closing of the AW acquisition, has an estimated fair value of $ 1.0 million as of the acquisition date. Pursuant to the Stock Purchase Agreement governing the AW acquisition, $ 10.0 million of the consideration was deposited into an escrow account to secure certain indemnification claims of DH, LLC. The assets acquired and liabilities assumed were recorded at their estimated preliminary fair values and the results of operations were included in the Company’s condensed consolidated results as of the acquisition date. The consideration transferred for the transaction is summarized as follows: (in thousands) Initial cash investment in December 2021 $ 40,000 Cash consideration paid at closing 58,645 Working capital adjustment ( 202 ) Contingent consideration 1,000 Purchase price $ 99,443 The contingent consideration is based on the achievement of certain expense control metrics during the two-year period following the acquisition date, with potential earn-out payouts ranging from $ 0 to $ 5.0 million. The Company estimated the fair value of the contingent consideration to be $ 1.0 million as of February 18, 2022, based on the estimated achievement of the expense control metrics, time to payment and market participant cost of debt. The contingent consideration was recorded in Other long-term liabilities in the accompanying condensed consolidated balance sheet as of June 30, 2022. Refer to Note 12. Fair Value Measurements . The purchase price allocations for the AW acquisition are provisional and are based on the information that was available as of the acquisition date to estimate the fair values of assets acquired and liabilities assumed. The purchase price allocations for this acquisition, reported as of June 30, 2022, represent the Company’s best estimates of the fair values and were based upon the information available to us. The Company is gathering and reviewing additional information necessary to finalize the values assigned to the acquired assets and liabilities assumed, as well as acquired identified intangible assets and goodwill. Therefore, the provisional measurements of fair values reported as of June 30, 2022 are subject to change. The Company is expected to finalize the purchase price allocations as soon as practicable, but no later than one year from the respective acquisition date. The preliminary allocation of the acquisition-date fair values of assets and liabilities pertaining to this business combination as of February 18, 2022, was as follows: (in thousands) Preliminary allocation: February 18, 2022 Cash $ 2,146 Accounts receivable 3,525 Prepaid expenses and other current assets 640 Property and equipment 134 Intangible assets 46,000 Right-of-use asset, operating leases 832 Other assets 703 Accounts payable and accrued expenses ( 821 ) Deferred revenue ( 3,365 ) Right-of-use liability, operating leases ( 832 ) Deferred taxes ( 10,135 ) Other liabilities ( 900 ) Total assets acquired and liabilities assumed 37,927 Goodwill 61,516 Purchase price $ 99,443 As a result of the AW acquisition, the Company recorded goodwill, customer relationships, developed software, and tradename of $ 61.5 million, $ 39.4 million, $ 6.1 million, and $ 0.5 million, respectively, as of the acquisition date. The goodwill recognized includes the fair value of the assembled workforce, which is not recognized as an intangible asset separable from goodwill, and any expected synergies gained through the acquisition. The Company determined that the goodwill resulting from the acquisition is not deductible for tax purposes. All goodwill has been allocated to the Company’s one reportable segment. Customer relationships represent the estimated fair value of the underlying relationships with the acquired entity’s business customers. The Company valued customer relationships using the income approach, specifically the multi-period excess earnings method. Significant assumptions include estimated attrition rates, discount rates, and tax rates reflecting the different risk profiles of the asset depending upon the acquisition. The value assigned to customer relationships is $ 39.4 million and is amortized using the annual pattern of cash flows (economic value method) over the estimated 20 -year life of this asset. The developed software represents AW’s two modules. Passport Promotional Analytics helps customers to optimize internal investment and business management by focusing on driving incremental efficiencies in sales, cost management, profit optimization, and productive gains. Passport Planning and Performance helps customers to analyze large data sets in order to proactively predict business outcomes. The Company used the income approach, specifically the relief-from-royalty method, to determine the value of developed software. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The developed software was valued at $ 6.1 million and is amortized using the straight-line method over the estimated remaining useful life of 6 years. The tradename represents the estimated fair value of the registered trade name associated with the AW corporate brand. The Company estimated the fair value of the trademark using a relief from royalty method of the income approach. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The trademark was valued at $ 0.5 million and is amortized using the straight-line method over the estimated remaining useful life of 5 years. The amortization periods for the customer relationships, developed software, and tradenames are 20 years, 6 years, and 5 years, respectively. See Note 9 for the estimated total intangible amortization expense during the next five years. In connection with the acquisition, the Company recognized acquisition related costs of $ 1.2 million which were recorded within transaction expenses in the accompanying condensed consolidated statements of operations for the six months ended June 30, 2022. During the six months ended June 30, 2022 and 2021, AW’s post-acquisition revenue and net loss on a standalone basis were not material . Unaudited Pro Forma Supplementary Data as if the transaction had occurred on January 1, 2021: Six Months Ended June 30, (in thousands) 2022 2021 Revenue $ 106,149 $ 81,765 Net loss ( 22,136 ) ( 26,582 ) These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the acquisition actually taken place on January 1, 2021. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the acquisition, including but not limited to revenue enhancements, cost savings or operating synergies that the combined Company may achieve as a result of the acquisition.

Revenue

Revenue	6 Months Ended
Revenue	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	4. Revenue The Company disaggregates revenue from its arrangements with customers by type of service as it believes these categories best depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following table represents a disaggregation of revenue from arrangements with customers for the three and six months ended June 30, 2022 and 2021, respectively: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Platform subscriptions $ 53,211 $ 39,400 $ 102,980 $ 75,765 Professional services 1,337 421 1,692 992 Total revenue $ 54,548 $ 39,821 $ 104,672 $ 76,757 The opening and closing balances of the Company’s receivables, deferred contract costs and contract liabilities from contracts with customers are as follows: (in thousands) June 30, December 31, Accounts receivable, net $ 31,734 $ 43,336 Deferred contract costs, current portion 8,469 6,880 Deferred contract costs, long-term 12,933 11,667 Deferred revenues 88,992 84,023 Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the six months ended June 30, 2022 and the year ended December 31, 2021 is presented below: (in thousands) Six Months Ended June 30, 2022 Twelve Months Ended December 31, 2021 Balance at beginning of period $ 18,547 $ 8,899 Costs amortized ( 3,991 ) ( 4,792 ) Additional amounts deferred 6,846 14,440 Balance at end of period 21,402 18,547 Classified as: Current 8,469 6,880 Non-current 12,933 11,667 Total deferred contract costs (deferred commissions) $ 21,402 $ 18,547 Contract Liabilities A summary of the activity impacting deferred revenue balances during the six months ended June 30, 2022 and for the year ended December 31, 2021 is presented below: (in thousands) Six Months Ended June 30, 2022 Twelve Months Ended December 31, 2021 Balance at beginning of period $ 84,023 $ 61,200 Revenue recognized ( 104,672 ) ( 166,154 ) Additional amounts deferred 109,641 188,977 Balance at end of period $ 88,992 $ 84,023 Remaining Performance Obligations Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue and unbilled amounts that will be invoiced and recognized as revenue in future periods. The Company expects to recognize approximately 64 % of the revenue within the next year and the remainder thereafter. The remaining performance obligations consisted of the following: (in thousands) June 30, December 31, Current $ 163,304 $ 155,134 Non-current 93,307 95,354 Total $ 256,611 $ 250,488

Leases

Leases	6 Months Ended
Leases	Jun. 30, 2022
Leases [Abstract]
Leases	5. Leases The Company leases real estate in the form of office space facilities. Generally, the term for real estate leases ranges from 1 to 9 years at inception of the contract. Some real estate leases include options to renew that can extend the original term by 5 to 10 years. Operating lease costs are allocated according to headcount to cost of revenue, sales and marketing, product development and general and administrative expenses in the condensed consolidated statements of operations. As of June 30, 2022 , the Company does no t have any finance leases. During the quarter ended March 31, 2022, the Company gave notice of its intent to extend one of its office lease facilities for an additional five-year period and the extension was accounted for as a lease modification under ASC 842. Accordingly, the Company recorded a right-of-use asset and corresponding operating lease liability of $ 6.0 million, which represented the present value of the expected future minimum lease payments. During the quarter ended June 30, 2022, the Company’s executive leadership team approved a program to exit the office lease facility and signed an agreement with the landlord to withdraw the Company’s exercise of the option to extend. As a result, the lease will terminate on December 31, 2022. This was accounted for as a lease modification under ASC 842 and the Company reduced the right-of-use asset by $ 6.0 million in the second quarter of 2022. The Company ceased use of the office facility during the quarter and accordingly recorded an impairment charge of $ 0.7 million, which represented the remaining carrying value of the right-of-use asset as of June 30, 2022. Also during the second quarter of 2022, the Company executed a plan to exit one of its office facilities by exercising an early termination clause, which was accounted for as a lease modification under ASC 842. The Company ceased use of the office facility during the quarter and accordingly recorded a $ 0.2 million impairment charge, which represented the remaining carrying value of the right-of-use asset. The Company recorded the following lease costs for the three and six months ended June 30, 2022: (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Lease Cost Capitalized operating lease cost $ 888 $ 1,723 Variable lease cost — 1 Total lease cost $ 888 $ 1,724 (in thousands) Supplemental Cash Flow and Other Information Cash paid for amounts included in measurement of lease liabilities and capitalized operating leases: Operating cash flows $ 1,544 Right-of-use assets obtained in exchange for lease liabilities: Capitalized operating leases $ 803 Lease term and discount rate consisted of the following at June 30, 2022: June 30, 2022 Weighted-average remaining lease term (in years): Capitalized operating leases 6.03 Weighted-average discount rate: Capitalized operating leases 4.2 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed consolidated balance sheets as of June 30, 2022. (in thousands) Capitalized Operating Lease 2022, excluding the six months ended June 30, 2022 $ 1,608 2023 1,898 2024 2,353 2025 2,147 2026 2,071 Thereafter 4,488 $ 14,565 Imputed interest 1,744 Lease liability balance at June 30, 2022 $ 12,821 Future aggregate minimum annual lease payments as of December 31, 2021 reported in our 2021 Form 10-K under the previous lease accounting standard were as follows: (in thousands) Operating Lease 2022 $ 3,120 2023 1,895 2024 2,282 2025 2,174 2026 2,165 Thereafter 4,805 $ 16,441 Total rent expense, which was allocated according to headcount to cost of revenue, sales and marketing, product development and general and administrative expenses in the condensed consolidated statements of operations, was $ 0.7 million in the three months ended June 30, 2022 and 2021 and $ 1.5 m illion and $ 1.3 m illion in the six months ended June 30, 2022 and 2021 , respectively.

Short-term Investments

Short-term Investments	6 Months Ended
Short-term Investments	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	6. Short-term Investments Short-term investments classified as available-for-sale consisted of the following: June 30, 2022 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 60,233 $ — $ ( 339 ) $ 59,894 Commercial paper 58,434 — ( 112 ) 58,322 Total short-term investments $ 118,667 $ — $ ( 451 ) $ 118,216 All short-term investments had stated maturity dates of less than one year

Accounts Receivable

Accounts Receivable	6 Months Ended
Accounts Receivable	Jun. 30, 2022
Receivables [Abstract]
Accounts Receivable	7. Accounts Receivable Accounts receivable consisted of the following: (in thousands) June 30, December 31, Accounts receivable $ 31,839 $ 44,303 Unbilled receivable 1,080 430 32,919 44,733 Less: allowance for doubtful accounts ( 1,185 ) ( 1,397 ) Accounts receivable, net $ 31,734 $ 43,336

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	8. Property and Equipment Property and equipment consisted of the following: (in thousands) June 30, December 31, Computers and software $ 5,306 $ 4,744 Furniture and equipment 1,653 1,580 Leasehold improvements 2,798 3,348 9,757 9,672 Less: accumulated depreciation and amortization ( 4,997 ) ( 4,603 ) Property and equipment, net $ 4,760 $ 5,069 Depreciation and amortization expense associated with property and equipment was $ 0.8 million and $ 0.4 million for the three months ended June 30, 2022 and 2021 , respectively, and $ 1.3 million and $ 0.7 million for the six months ended June 30, 2022 and 2021, respectively. During the three and six months ended June 30, 2022 , in relation to our office relocations, the Company recorded an impairment charge of $ 1.0 million, comprised of $ 0.9 million relating to the operating lease right-of-use assets, and $ 0.1 million relating to the leasehold improvements. The Company also recorded accelerated depreciation of computer equipment of $ 0.2 million. These charges were recognized within Transaction and restructuring expenses in the Company’s condensed consolidated statements of operations. In connection with the office relocations, the Company disposed of $ 1.0 million of fully-depreciated property and equipment in the second quarter of 2022.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
Goodwill and Intangible Assets	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets The carrying amounts of goodwill and intangible assets, as of June 30, 2022 and December 31, 2021, consist of the following: June 30, 2022 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 409,430 $ ( 110,696 ) $ 298,734 Developed technologies 57,200 ( 21,453 ) 35,747 Tradenames 36,000 ( 6,096 ) 29,904 Database 46,580 ( 38,769 ) 7,811 Total finite-lived intangible assets 549,210 ( 177,014 ) 372,196 Goodwill 1,322,959 — 1,322,959 Total goodwill and Intangible assets $ 1,872,169 $ ( 177,014 ) $ 1,695,155 December 31, 2021 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 370,030 $ ( 92,942 ) $ 277,088 Developed technologies 51,100 ( 17,475 ) 33,625 Tradenames 35,500 ( 5,034 ) 30,466 Database 43,080 ( 31,789 ) 11,291 Total finite-lived intangible assets 499,710 ( 147,240 ) 352,470 Goodwill 1,261,444 — 1,261,444 Total goodwill and Intangible assets $ 1,761,154 $ ( 147,240 ) $ 1,613,914 Amortization expense associated with finite-lived intangible assets wa s $ 15.1 m illion and $ 14.5 million for the three months ended June 30, 2022 and 2021, respectively, of which $ 5.6 million and $ 5.3 million was included in cost of revenue for the respective periods. Amortization expense associated with finite-lived intangible assets wa s $ 29.8 m illion and $ 28.8 million for the six months ended June 30, 2022 and 2021, respectively, of which $ 11.0 million and $ 10.5 million was included in cost of revenue for the respective periods. Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2022, excluding the six months ended June 30, 2022 $ 25,520 2023 48,216 2024 45,369 2025 41,419 2026 34,878 Thereafter 176,794 Total $ 372,196 The carrying amount of goodwill increased by $ 61.5 million during the six months ended June 30, 2022 as a result of the of AW acquisition (Note 3). The Company determined it had one reporting unit. There was no impairment of goodwill in the six months ended June 30, 2022 or 2021 .

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	6 Months Ended
Derivative Instruments and Hedging Activities	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	10. Derivative Instruments and Hedging Activities Risk Management Objective of Using Derivatives The Company is exposed to risks from changes in interest rates related to the 2021 Term Loan (See Note 11. Long-Term Debt ). The Company uses derivative financial instruments, specifically, interest rate swap contracts, in order to manage its exposure to interest rate movements. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Our primary objective in holding derivatives is to reduce the volatility of cash flows associated with changes in interest rates. The Company does not enter into derivative transactions for speculative or trading purposes. Cash Flow Hedges of Interest Rate Risk In March of 2022, the Company entered into two interest rate swap agreements. As of June 30, 2022 , the two outstanding interest rate swap agreements each had a notional value of $ 67.5 million. The Company has not recorded any amounts due to ineffectiveness for the six months ended June 30, 2022 . The notional value of each interest rate swap agreement is expected to match the corresponding principal amount of a portion of our borrowings under the 2021 Term Loan. The swap agreements became effective as of March 31, 2022 and mature on March 31, 2025 . During this period, the two notional amounts will have fixed interest rates of 2.0135 % and 2.012 %, and the counterparties to each of the agreements will pay the Company interest at a floating rate based on the one-month USD-LIBOR swap rate on the notional amounts. Interest payments will be made monthly on a net settlement basis. The derivative interest rate swaps are designated and qualify as cash flow hedges. Consequently, the change in the estimated fair value of the effective portion of the derivative is recognized in accumulated other comprehensive income (“AOCI”) on our Condensed Consolidated Balance Sheets and reclassified to interest expense, net, when the underlying transaction has an impact on earnings. The Company expects to recognize approximately $ 1.5 million of net pre-tax gains from accumulated other comprehensive income as a reduction of interest expense in the next twelve months associated with its interest rate swap. The Company recognizes derivative instruments and hedging activities on a gross basis as either assets or liabilities on the Company’s Condensed Consolidated Balance Sheets and measures them at fair value. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the earnings effect of the hedged forecasted transactions in a cash flow hedge. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The fair values of the interest rate swaps and their respective locations in our condensed consolidated balance sheets at June 30, 2022 were as follows: (in thousands) Description Balance Sheet Location June 30, 2022 Short-term derivative asset Prepaid expenses and other current assets $ 1,453 Long-term derivative asset Other assets 1,887

Long-term Debt

Long-term Debt	6 Months Ended
Long-term Debt	Jun. 30, 2022
Long-Term Debt, Unclassified [Abstract]
Long-Term Debt	11. Long-Term Debt Long-term debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively: June 30, 2022 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 269,844 $ ( 2,323 ) $ 267,521 Less: current portion of long-term debt 6,875 Long-term debt $ 260,646 December 31, 2021 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 273,282 $ ( 2,599 ) $ 270,683 Less: current portion of long-term debt 6,875 Long-term debt $ 263,808 During the six months ended June 30, 2022 , the Company repaid $ 3.4 million in outstanding principal of the 2021 Term Loan, and related accrued interest payable of $3.9 million. 2021 Credit Agreement In September 2021, DH Holdings entered into a credit agreement (the "2021 Credit Agreement") with Bank of America, N.A., as administrative agent, the other lenders party thereto and the other parties specified therein. The 2021 Credit Agreement provides for (i) a $275.0 million term loan A facility (the "2021 Term Loan") and (ii) a $ 75.0 million revolving credit facility (the "2021 Revolving Line of Credit" and, together with the 2021 Term Loan, collectively, the "2021 Credit Facilities"), the proceeds of which were used to repay a portion of the indebtedness outstanding under a previous credit agreement. Both the 2021 Term Loan and the 2021 Revolving Line of Credit mature on September 17, 2026 . The 2021 Credit Facilities include customary affirmative, negative and financial covenants. The 2021 Credit Facilities are guaranteed by all of DH Holdings' wholly-owned domestic restricted subsidiaries and AIDH Buyer, a Delaware limited liability company and the direct parent company of DH Holdings, in each case, subject to customary exceptions, and are secured by a lien on substantially all of the assets of DH Holdings and the guarantors, including a pledge of the equity of DH Holdings, in each case, subject to customary exceptions. The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the "Initial Amortization Date"), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year and fifth year after the Initial Amortization Date. A balloon payment of approximately $ 220.0 million will be due at the maturity of the 2021 Term Loan. There was $ 269.8 million outstanding on the 2021 Term Loan at June 30, 2022. DH Holdings is required to pay the lenders under the 2021 Credit Agreement an unused commitment fee of between 0.25 % and 0.30 % per annum on the undrawn commitments under the 2021 Revolving Line of Credit, depending on the total net leverage ratio, quarterly in arrears. The expense is included in interest expense in the statements of operations. There was no outstanding balance on the 2021 Revolving Line of Credit at June 30, 2022. For both the 2021 Term Loan and 2021 Revolving Line of Credit, DH Holdings may elect from several interest rate options based on the LIBO Rate or the Base Rate plus an applicable margin. The applicable margin will be based on the total leverage ratio beginning in the fiscal year ended December 31, 2022. As of June 30, 2022 , the effective interest rate was 3.92 %. In connection with the 2021 Credit Agreement, the Company capitalized financing costs totaling $ 3.5 million, $ 2.8 million for the 2021 Term Loan facility and $ 0.8 million for the 2021 Revolving Line of Credit. The financing costs associated with the 2021 Term Loan facility are recorded as a contra-debt balance in Term loan, net of current portion in the condensed consolidated balance sheets and are amortized over the remaining life of the loan using the effective interest method. The financing costs associated with the 2021 Revolving Line of Credit are recorded in Other assets in the condensed consolidated balance sheet are amortized over the life of the arrangement. At June 30, 2022, the unamortized financing costs were $ 0.6 million.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received for an asset, or paid to transfer a liability, in an orderly transaction between market participants on the measurement date, and establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value as follows: Level 1 - Observable inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs that are supported by little or no market activity, including the Company’s own assumptions in determining fair value. The Company’s financial assets and liabilities subject to the three-level fair value hierarchy consist principally of cash and equivalents, short-term investments, accounts receivable, accounts payable, long-term and short-term debt and contingent consideration payable. The estimated fair value of cash included in cash and cash equivalents, accounts receivable and accounts payable approximates their carrying value due to due to their short maturities (less than 12 months). Debt The Company’s short- and long-term debt are recorded at their carrying values in the condensed consolidated balance sheets, which may differ from their respective fair values. The carrying values and estimated fair values of the Company’s short- and long-term debt approximate their carrying values as of June 30, 2022 and December 31, 2021, based on interest rates currently available to the Company for similar borrowings. Money market funds (included in cash and cash equivalents) Money market funds are recorded at fair value using quoted market prices in active markets and are classified as Level 1 in the fair value hierarchy. Short-term investments The Company utilizes a third-party pricing service for the valuation of its short-term investments. U.S. treasuries consist of short-term treasury bills that are recorded at fair value using market information obtained from dealers and brokers and classified in Level 2 of the fair value hierarchy. Commercial paper is carried at fair value, which is determined using a market yield curve-based approach based on observable inputs. Commercial paper is classified as Level 2 in the fair value hierarchy. Derivative financial instruments Currently, the Company uses interest rate swaps to manage interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. To comply with the provisions of ASC 820, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. The Company has determined that the significance of the impact of the credit valuation adjustments made to its derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of its derivatives held as of June 30, 2022 were classified as Level 2 in the fair value hierarchy. Contingent consideration The deferred consideration that resulted from the acquisition of Analytical Wizards in the first quarter of 2022, which is subject to the meeting of certain expense control metrics during the two-year period following the AW acquisition, is measured at fair value on a recurring basis. The fair value was estimated based on the present value of the amount expected to be paid at the end of the measurement period. At June 30, 2022, the fair value of the contingent consideration was estimated to be $ 1.0 million and is included in other long-term liabilities on the condensed consolidated balance sheet. The contingent consideration that resulted from the earn-outs associated with the acquisition of Monocl Holding Company in October of 2020, which was included in accrued expense and other current liabilities in the condensed consolidated balance sheet as of December 31, 2021 was paid in the first quarter of 2022. Earnout liabilities are classified within Level 3 in the fair value hierarchy because the methodology used to develop the estimated fair value includes significant unobservable inputs reflecting management’s own assumptions. The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) June 30, December 31, Balance at beginning of period $ 7,500 $ 5,236 Additions 1,000 — Net change in fair value and other adjustments — 3,764 Payments ( 7,500 ) ( 1,500 ) Balance at end of period $ 1,000 $ 7,500 Non-recurring fair value measurements Certain assets and liabilities, including property, plant and equipment, lease right-of-use assets, goodwill and other intangible assets, are measured at fair value on a non-recurring basis. These assets are remeasured when the derived fair value is below the carrying value on the Company’s condensed consolidated balance sheet. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. When impairment has occurred, the Company measures the required charges and adjusts the carrying value as discussed in Note 2. Summary of Significant Accounting Policies of the notes to the consolidated financial statements in the Company’s 2021 Form 10-K. During the three and six months ended June 30, 2022, in relation to our office relocations, the Company recorded an impairment charge of $ 1.0 million, comprised of $ 0.9 million relating to the operating lease right-of-use assets, and $ 0.1 million relating to the leasehold improvements. The fair value determination was based on valuation techniques using the best information available and included comparable market information and discounted cash flow projections. At June 30, 2022, additional assets and liabilities measured at fair value on a recurring basis were as follows: (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 432 $ 432 $ — $ — Commercial paper (maturities less than 90 days) 7,990 — 7,990 — Short-term investments: U.S. Treasuries 59,894 — 59,894 — Commercial paper 58,322 — 58,322 — Prepaid expenses and other current assets: Interest rate swap contracts 1,453 — 1,453 — Other Assets: Interest rate swap contracts 1,887 — 1,887 — Liabilities: Other long-term liabilities: Contingent consideration 1,000 — — 1,000 At December 31, 2021, except for the contingent consideration noted above, the estimated fair values of all of the Company’s financial assets and liabilities subject to the three-level fair value hierarchy approximated their carrying values due to their short-term maturities (less than 12 months).

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
Accrued Expenses and Other Current Liabilities	Jun. 30, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	13. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: (in thousands) June 30, December 31, Payroll and payroll-related $ 7,403 $ 10,311 Contingent consideration, current — 7,500 Sales, franchise and other taxes 3,133 1,785 Other 4,146 3,062 Accrued expenses and other current liabilities $ 14,682 $ 22,658

Noncontrolling Interest

Noncontrolling Interest	6 Months Ended
Noncontrolling Interest	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Noncontrolling Interest	14. Noncontrolling Interest Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo, and reports the noncontrolling interests of its consolidated subsidiaries on its condensed consolidated financial statements based on the Definitive OpCo Units held by Continuing LLC Members. Changes in Definitive Healthcare Corp.'s ownership interest in its consolidated subsidiaries are accounted for as equity transactions. As such, future redemptions or direct exchanges of Definitive OpCo Units by Continuing LLC Members will result in a change in ownership and reduce or increase the amount recorded as noncontrolling interests and increase or decrease additional paid-in capital in the Company’s Condensed Consolidated Balance Sheets. During the six months ended June 30, 2022 , 3,442,891 Definitive OpCo Units held by Continuing LLC Members were exchanged for shares of Class A Common Stock of Definitive Healthcare Corp. pursuant to the terms of the Amended LLC Agreement. In addition, 11,729 restricted stock units vested, resulting in the issuance of 11,729 shares of Class A Common Stock of Definitive Healthcare Corp., for which Definitive OpCo Units were issued on a one-for-one basis pursuant to the Definitive OpCo second amended and restated limited liability company agreement entered into in connection with the IPO. As of June 30, 2022, Definitive Healthcare Corp. h eld 100,484,715 units in the Definitive OpCo resulting in an ownership interest of 65.8 % and a noncontrolling interest of 34.2 % .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
Accumulated Other Comprehensive Loss	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	15. Accumulated Other Comprehensive Loss The following table summarize the changes in accumulated balances of other comprehensive loss for the three and six months ended June 30, 2022 and 2021, respectively. Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 (in thousands) Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 1,049 $ ( 197 ) $ 66 $ 918 $ — $ — $ 62 $ 62 Other comprehensive income (loss) before reclassifications 825 ( 93 ) 68 800 1,874 ( 290 ) 72 1,656 Amounts reclassified from AOCI 276 — — 276 276 — — 276 Ending balance at June 30, 2022 $ 2,150 $ ( 290 ) $ 134 $ 1,994 $ 2,150 $ ( 290 ) $ 134 $ 1,994 Three months ended June 30, 2021 Six months ended June 30, 2021 (in thousands) Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ — $ — $ 32 $ 32 $ — $ — $ ( 131 ) $ ( 131 ) Other comprehensive income (loss) — — ( 19 ) ( 19 ) — — 144 144 Ending balance at June 30, 2021 $ – – $ – – $ 13 $ 13 $ – – $ – – $ 13 $ 13

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
Equity-Based Compensation	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	16. Equity-Based Compensation Equity-based compensation expense is allocated to all departments based on the recipients of the compensation. A summary of the expense by line item in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively, is provided in the following table. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 230 $ 16 $ 462 $ 31 Sales and marketing 5,056 139 8,802 241 Product development 1,841 78 3,130 154 General and administrative 1,878 1,382 3,483 1,595 Total compensation expense $ 9,005 $ 1,615 $ 15,877 $ 2,021 2021 Equity Incentive Plan The Definitive Healthcare Corp. 2021 Equity Incentive Plan (the “2021 Plan”) was adopted in September 2021. The types of grants available under the 2021 Plan include stock options (both incentive and non-qualified), stock appreciation rights ("SARs"), restricted stock awards ("RSAs"), restricted stock units ("RSUs"), and stock-based awards. The aggregate number of shares of Class A Common Stock available for grant under the 2021 Plan was 5,214,689 sha res at June 30, 2022. As of June 30, 2022, 3,774,350 sh ares have been granted under the 2021 Plan, net of forfeitures. The outstanding RSUs have time-based and/or performance-based vesting criteria. Time-Based RSUs Outstanding time-based RSUs generally vest partially on the one-year anniversary of each grant and quarterly over the subsequent two- or three-year period. The following table summarizes the Company’s unvested time-based RSU activity for the six months ended June 30, 2022: Time-Based RSUs Weighted Restricted Average Grant Stock Units Date Fair Value Unvested at December 31, 2021 1,935,899 $ 32.59 Granted 1,659,216 22.74 Vested ( 11,729 ) 17.11 Forfeited ( 100,857 ) 26.65 Unvested at June 30, 2022 3,482,529 $ 28.12 The Company reco gnized $ 7.0 million and $ 12.1 millio n in stock-based compensation expense associated with time-based RSUs in the three and six months ended June 30, 2022, respectively. Total unrecognized expense for these awards was estimated to be $ 81.6 m illion at June 30, 2022, to be recognized over a weighted-average period of approximately 2.9 y ears. Performance-Based RSUs (“PSUs”) The Company periodically grants PSUs to certain members of the Company’s senior management team subject to the satisfaction of annual and cumulative performance conditions and/or market conditions established by the Human Capital Management and Compensation Committee of the Board of Directors of Definitive Healthcare Corp. Those PSUs without market-based vesting conditions vest annually over three years subject to the achievement of certain performance targets and continued service. Expense for these awards is recognized when it becomes probable that performance measures triggering vesting will be achieved. In May 2022, the Company granted PSUs to a member of the executive leadership team with performance criteria related to the relative ranking of the total stockholder return (“TSR”) of the Company’s common stock for the cumulative three-year performance period return relative to the TSR of certain peer companies within the Nasdaq Software & Services Index. TSR will be measured based on the 20-trading-day average closing stock price on the first day of the performance period compared to the 20-trading-day average closing stock price on the last day of such period, inclusive of applicable cash dividend payments. These PSUs subject to the performance criteria will cliff vest after three years, subject to the satisfaction of the performance criteria and the executive’s continued employment through the performance period. PSUs may vest in a range between 0 % and 300 %, based on the satisfaction of performance, and no shares will be issued if the minimum applicable performance metric is not achieved. As these PSUs vest based on the achievement of market conditions, the grant date fair values were determined using a Monte-Carlo valuation model. The Monte-Carlo valuation model considered a variety of potential future share prices for the Company as well as its peer companies in the selected market index. Expense for these awards is recognized ratably over the requisite service period based on the fair value of the award. The following table summarizes the Company’s unvested PSU activity for the six months ended June 30, 2022. Performance-Based PSUs Weighted Restricted Average Grant Stock Units Date Fair Value Unvested at December 31, 2021 164,351 $ 27.00 Granted 125,000 54.25 Vested — — Forfeited ( 9,259 ) 27.00 Unvested at June 30, 2022 280,092 $ 39.16 The number of PSUs awarded represents the target number of shares of common stock that may be earned; however, the actual number of shares may vary based on the satisfaction of performance criteria. The Company recognized $ 0.5 m illion and $ 0.7 m illion in stock-based compensation expense associated with PSUs in the three and six months ended June 30, 2022, respectively. Total unrecognized expense for the se awards was estimated to be $ 8.1 million at June 30, 2022 , to be recognized over a weighted-average period of approximately 2.0 y ears. 2019 Equity Incentive Plan The AIDH Topco, LLC 2019 Equity Incentive Plan (the “2019 Plan”) was utilized prior to the Reorganization Transactions and the IPO for the issuance of equity awards in the form of Class B units to employees, consultants, directors, managers, or others providing services to the Company. In connection with the Reorganization Transactions and the IPO, unvested Class B Units held directly by employees of the Company or indirectly through Definitive OpCo, were exchanged for unvested Definitive OpCo units based on their respective participation thresholds and the IPO price of $ 27.00 per share. The Company no longer grants any awards under the 2019 Plan, though previously granted awards under the 2019 Plan remain outstanding and governed by the 2019 Plan, including unvested units. The following table summarizes the Company’s unvested unit activity. Time-Based Weighted Non-Vested Average Grant Units Date Fair Value Unvested at December 31, 2021 2,756,406 $ 2.02 Granted — — Vested ( 150,862 ) 1.58 Forfeited ( 56,356 ) 1.75 Unvested at June 30, 2022 2,549,188 $ 2.06 The Company rec orded $ 1.5 million and $ 3.0 milli on in stock-based compensation expense associated with these units in the three and six months ended June 30, 2022, respectively. The Company recorded $ 0.6 million and $ 1.0 million in stock-based compensation expense associated with these units in the three and six months ended June 30, 2021, respectively. At June 30, 2022, the Company had approximately $ 12.1 m illion of unrecognized unit-based compensation expense for unvested units, which is expected to be recognized over a weighted-average period of approximately 2.1 y ears.

Retirement Plans

Retirement Plans	6 Months Ended
Retirement Plans	Jun. 30, 2022
Retirement Benefits [Abstract]
Retirement Plans	17. Retirement Plan The Company has a 401(k) plan covering all employees who have met certain eligibility requirements. The Company made matching contributions in accordance with the plan documents. The Company incurre d $ 0.8 million and $ 1.9 million in employer matching contributions during the three and six months ended June 30, 2022, respectively, and $ 0.5 million and $ 1.2 million during the three and six months ended June 30, 2021 , respectively.

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes During the six months ended June 30, 2022, management performed an assessment of the recoverability of deferred tax assets. Management determined, based on the accounting standards applicable to such assessment, that there was sufficient negative evidence as a result of the Company’s scheduled reversal of deferred tax liabilities and cumulative losses to conclude it was more likely than not that its deferred tax assets would not be realized and has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized. In the event that management was to determine that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, an adjustment to the valuation allowance would be made which would reduce the provision for income taxes. As of June 30, 2022 , the Company has recorded a net deferred tax liability of $ 85.6 million, of which $1 0.1 million was recorded as a result of the AW acquisition. The net deferred tax liability reflects a valuation allowance against deferred tax assets that are more likely than not to not be realized as well as reversing taxable temporary differences that will not provide a source of taxable income due to attribute limitation rules. The Company recognizes uncertain income tax positions when it is more-likely-than-not the position will be sustained upon examination. As of June 30, 2022 and December 31, 2021 , the Company has no t identified any uncertain tax positions and has not recognized any related reserves. The Company's effective tax rate was 2.2 % and 0.0 % for the three months ended June 30, 2022 and 2021 , respectively, and 0.6 % and 0.0 % for the six months ended June 30, 2022 and 2021 , respectively. The Company’s effective tax rate differs from the statutory tax rate of 21 % due to partnership income that is not taxed, the valuation allowance recorded, and foreign tax rates that differ from the U.S. statutory tax rate. Tax Receivable Agreement Pursuant to the Company's election under Section 754 of the Internal Revenue Code (the "Code"), the Company expects to obtain an increase in its share of the tax basis in the net assets of AIDH Topco, LLC when LLC Interests are redeemed or exchanged by other members. The Company plans to make an election under Section 754 of the Code for each taxable year in which a redemption of exchange of LLC Interest occurs. The Company intends to treat any redemptions and exchanges of LLC Interest as direct purchases of LLC Interests for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that would otherwise be paid in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. In connection with the IPO, the Company entered into a Tax Receivable Agreement ("TRA") and has recorded a liability under the TRA of $ 155.9 milli on as of June 30, 2022. During the three and six months ended June 30, 2022 , the Company recognized a TRA remeasurement gain of $ 3.4 million and $ 3.1 million within Other income (expense), net in the Company’s condensed consolidated statements of operations. Under the TRA, the Company generally will be required to pay to the Original LLC Unitholders 85 % of the amount of cash savings, if any, in U.S. federal, state, or local tax that the Company actually realizes directly or indirectly (or are deemed to realize in certain circumstances) as a result of (i) certain tax attributes created as a result of any sales or exchanges (as determined for U.S. federal income tax purposes) to or with the Company of their interests in AIDH TopCo, LLC, including any basis adjustment relating to the assets of AIDH TopCo, LLC, (ii) existing tax attributes acquired by the Company in the pre-IPO restructuring, and (iii) tax benefits attributable to payments made under the TRA. The Company expects to benefit from the remaining 15 % of any tax benefits that it may actually realize. To the extent that the Company is unable to timely make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid. No amounts are expected to be paid within the next 12 months.

Loss Per Share

Loss Per Share	6 Months Ended
Loss Per Share	Jun. 30, 2022
Earnings Per Share [Abstract]
Loss Per Share	19. Loss Per Share Basic net loss per share of Class A Common Stock is computed by dividing net income attributable to Definitive Healthcare Corp. by the weighted-average number of shares of Class A Common Stock outstanding during the period, excluding unvested equity awards and subsidiary member units not exchanged. Diluted earnings per share of Class A Common Stock is calculated by dividing net income attributable to Definitive Healthcare Corp, adjusted for the assumed exchange of all potentially dilutive securities by the weighted-average number of shares of Class A Common Stock outstanding. Prior to the IPO, the Definitive OpCo membership structure included Class A and Class B member units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO and determined that it resulted in values that would not be meaningful to the readers of these unaudited condensed consolidated financial statements. Therefore, earnings per share information has not been presented for the three and six months ended June 30, 2021. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and six months ended June 30, 2022 . (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Numerator: Net loss $ ( 9,579 ) $ ( 22,636 ) Less: Net loss attributable to noncontrolling interests ( 4,429 ) ( 8,862 ) Net loss attributable to Definitive Healthcare Corp. $ ( 5,150 ) $ ( 13,774 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and six months ended June 30, 2022 (per share amounts unaudited). (in thousands, except number of shares and per share amounts) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 5,150 ) $ ( 13,774 ) Weighted average number of shares of Class A Common Stock outstanding 99,203,697 98,186,909 Net loss per share, basic and diluted $ ( 0.05 ) $ ( 0.14 ) Shares of the Company’s Class B Common Stock do not participate in the earnings or losses of Definitive Healthcare Corp. and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B Common Stock under the two-class method has not been presented. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2022 Definitive OpCo Units (vested and unvested) 54,745,380 Restricted Stock Units 3,762,621

Segment and Geographic Data

Segment and Geographic Data	6 Months Ended
Segment and Geographic Data	Jun. 30, 2022
Segment Reporting [Abstract]
Segment and Geographic Data	20. Segment and Geographic Data The Company operates as one operating segment. Operating segments are defined as components of the Company for which separate financial information is available and evaluated regularly by the Company’s chief operating decision maker in deciding how to allocate resources and in assessing performance. The chief operating decision maker for the Company is the chief executive officer. The chief executive officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by type of service and geographic region, for purposes of allocating resources and evaluating financial performance. Revenues by geographic area presented based upon the location of the customer are as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 United States $ 52,028 $ 38,489 $ 99,608 $ 74,186 Rest of world 2,520 1,332 5,064 2,571 Total revenues $ 54,548 $ 39,821 $ 104,672 $ 76,757 For a summary of our revenue disaggregated by service, refer to Note 4. Revenue . Long-lived assets by geographical region are based on the location of the legal entity that owns the assets. Long-lived assets by geographic area presented based upon the location of the assets are as follows: (in thousands) June 30, December 31, United States $ 4,272 $ 4,705 Rest of world 488 364 Total long-lived assets $ 4,760 $ 5,069

Related Parties

Related Parties	6 Months Ended
Related Parties	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Parties	21. Related Parties The Company has engaged in revenue transactions within the ordinary course of business with entities affiliated with its private equity Sponsors and with members of the Company’s board of directors. During each of the three months ended June 30, 2022 and 2021 the Company recorded revenue of $ 0.2 million and $ 0.3 million, respectively. During each of the six months ended June 30, 2022 and 2021 the Company recorded revenue of $ 0.4 million. There was no associated receivable for the revenue transactions at June 30, 2022 . The associated receivable for the revenue transactions amounted to $ 0.6 million at December 31, 2021. In the second quarter of 2022, the Company entered into a licensed data master agreement with a data provider, in which one of the Company’s affiliates has an indirect financial ownership interest via a minority investment, to provide licensed data. The agreement is effective through August 31, 2025, and the Company has not incurred costs associated with this agreement in the quarter ending June 30, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 are unaudited. Amounts for the period from January 1, 2021 through June 30, 2021 presented in the condensed consolidated financial statements and notes to the condensed consolidated financial statements herein represent the historical operations of Definitive OpCo. The amounts as of June 30, 2022 and December 31, 2021 and for the period from January 1, 2022 through June 30, 2022 reflect the consolidated operations of Definitive Healthcare Corp. and its consolidated subsidiaries. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered necessary for a fair presentation of the unaudited interim condensed consolidated financial statements for these interim periods have been included. Refer to Note 2 below and to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 for the Company’s significant accounting policies and estimates.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations and useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates.
Leases	Leases Effective January 1, 2022, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02— Leases (Topic 842) (“ASC 842”) . In accordance with ASC 842, the Company, at the inception of the contract, determines whether a contract is or contains a lease. For leases with terms greater than 12 months, the Company records the related operating or finance right of use asset and lease liability at the present value of lease payments over the lease term. The Company is generally not able to readily determine the implicit rate in the lease and therefore uses the determined incremental borrowing rate at lease commencement to determine the present value of lease payments. The incremental borrowing rate represents an estimate of the market interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. Renewal options are not included in the measurement of the right of use assets and lease liabilities unless the Company is reasonably certain to exercise the optional renewal periods. Some leases also include early termination options, which can be exercised under specific conditions. Additionally, certain leases contain incentives, such as construction allowances from landlords. These incentives reduce the right-of-use asset related to the lease. Some of the Company's leases contain rent escalations over the lease term. The Company recognizes expense for operating leases on a straight-line basis over the lease term. The Company’s lease agreements contain variable lease payments for common area maintenance, utility, and taxes. The Company has elected the practical expedient to combine lease and non-lease components for all asset categories. Therefore, the lease payments used to measure the lease liability for these leases include fixed minimum rentals along with fixed non-lease component charges. The Company does not have significant residual value guarantees or restrictive covenants in the lease portfolio.
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities FASB Accounting Standards Codification (“ASC”) 815— Derivatives and Hedging (“ASC 815”), provides the disclosure requirements for derivatives and hedging activities with the intent to provide users of financial statements with an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how the entity accounts for derivative instruments and related hedged items, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. Further, qualitative disclosures are required that explain the Company’s objectives and strategies for using derivatives, as well as quantitative disclosures about the fair value of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative instruments. As required by ASC 815, the Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting. In accordance with the FASB’s fair value measurement guidance in ASU 2011-04— Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (“ASC 820”), th e Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.
Adoption of Recently Issued Financial Accounting Standards	Adoption of Recently Issued Financial Accounting Standards In October 2021, the FASB issued ASU No. 2021-08— Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This new accounting standard requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606— Revenue from Contracts with Customers . The standard requires the acquirer to recognize contract assets and contract liabilities at the same amounts recorded by the acquiree. The new accounting guidance is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this new accounting guidance effective January 1, 2022. In connection with the acquisition of Analytical Wizards completed in the first quarter of 2022, the Company recorded contract liabilities of $ 3.4 million. Refer to Note 3. Acquisitions for further details. In December 2019, the FASB issued ASU No. 2019-12— Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes. This standard removes certain exceptions for investments, intra-period allocations and interim tax calculations and adds guidance to reduce complexity in accounting for income taxes. The amendment is effective for fiscal years beginning after December 15, 2021. The Company adopted this new accounting guidance effective January 1, 2022, but the adoption did not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02— Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company adopted ASU No. 2016-02— Leases effective January 1, 2022 using the modified retrospective transition method. Prior period results will continue to be presented under ASC 840 as it was the accounting standard in effect for such periods. The Company elected to apply the package of practical expedients that allows entities to forgo reassessing at the transition date: (1) whether any expired or existing contracts are or contain leases; (2) lease classification for any expired or existing leases; and (3) whether unamortized initial direct costs for existing leases meet the definition of initial direct costs under the new guidance. The Company did not elect the hindsight practical expedient. The Company elected to use the practical expedient that allows the combination of lease and non-lease contract components in all of its underlying asset categories. Finally, the Company also elected a policy of not recording leases on its condensed consolidated balance sheets when the leases have a term of 12 months or less and the Company is not reasonably certain to elect an option to renew the leased asset. Due to the adoption of this guidance, the Company recognized operating right-of-use assets of $ 12.7 million and operating lease liabilities of $ 14.0 million as of the date of adoption. The difference between the right-of-use assets and lease liabilities on the accompanying condensed consolidated balance sheet is primarily due to the accrual for lease payments as a result of straight-line lease expense and unamortized tenant incentive liability balances. The Company did not have any impact to opening retained earnings as a result of the adoption of the guidance. The adoption of this new guidance did not have a material impact on the Company’s results of operations, comprehensive loss, cash flows, liquidity or the Company’s covenant compliance under its existing credit agreement. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13 —Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments. This standard is intended to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope, such as trade receivables. The amendment is effective for fiscal years beginning after December 15, 2022. The Company will adopt the update effective January 1, 2023 and does not expect the adoption of the standard to have a material impact on its consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04— Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The amendments of ASU No. 2020-04 are effective for companies as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. The amendments in this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform and provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The Company is evaluating the impact that the amendments of this standard would have on its consolidated financial position or results of operations upon adoption.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
Acquisitions (Tables)	Jun. 30, 2022
Business Combinations [Abstract]
Summary of Transaction Transferred	The consideration transferred for the transaction is summarized as follows: (in thousands) Initial cash investment in December 2021 $ 40,000 Cash consideration paid at closing 58,645 Working capital adjustment ( 202 ) Contingent consideration 1,000 Purchase price $ 99,443
Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired	The preliminary allocation of the acquisition-date fair values of assets and liabilities pertaining to this business combination as of February 18, 2022, was as follows: (in thousands) Preliminary allocation: February 18, 2022 Cash $ 2,146 Accounts receivable 3,525 Prepaid expenses and other current assets 640 Property and equipment 134 Intangible assets 46,000 Right-of-use asset, operating leases 832 Other assets 703 Accounts payable and accrued expenses ( 821 ) Deferred revenue ( 3,365 ) Right-of-use liability, operating leases ( 832 ) Deferred taxes ( 10,135 ) Other liabilities ( 900 ) Total assets acquired and liabilities assumed 37,927 Goodwill 61,516 Purchase price $ 99,443
Schedule of Business Acquisition, Pro Forma Information	Unaudited Pro Forma Supplementary Data as if the transaction had occurred on January 1, 2021: Six Months Ended June 30, (in thousands) 2022 2021 Revenue $ 106,149 $ 81,765 Net loss ( 22,136 ) ( 26,582 )

Revenue (Tables)

Revenue (Tables)	6 Months Ended
Revenue (Tables)	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table represents a disaggregation of revenue from arrangements with customers for the three and six months ended June 30, 2022 and 2021, respectively: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Platform subscriptions $ 53,211 $ 39,400 $ 102,980 $ 75,765 Professional services 1,337 421 1,692 992 Total revenue $ 54,548 $ 39,821 $ 104,672 $ 76,757
Summary of Receivables, Deferred Contract Costs and Contract Liabilities from Contract with Customers	The opening and closing balances of the Company’s receivables, deferred contract costs and contract liabilities from contracts with customers are as follows: (in thousands) June 30, December 31, Accounts receivable, net $ 31,734 $ 43,336 Deferred contract costs, current portion 8,469 6,880 Deferred contract costs, long-term 12,933 11,667 Deferred revenues 88,992 84,023 Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the six months ended June 30, 2022 and the year ended December 31, 2021 is presented below: (in thousands) Six Months Ended June 30, 2022 Twelve Months Ended December 31, 2021 Balance at beginning of period $ 18,547 $ 8,899 Costs amortized ( 3,991 ) ( 4,792 ) Additional amounts deferred 6,846 14,440 Balance at end of period 21,402 18,547 Classified as: Current 8,469 6,880 Non-current 12,933 11,667 Total deferred contract costs (deferred commissions) $ 21,402 $ 18,547
Summary of Deferred Revenue Balances	A summary of the activity impacting deferred revenue balances during the six months ended June 30, 2022 and for the year ended December 31, 2021 is presented below: (in thousands) Six Months Ended June 30, 2022 Twelve Months Ended December 31, 2021 Balance at beginning of period $ 84,023 $ 61,200 Revenue recognized ( 104,672 ) ( 166,154 ) Additional amounts deferred 109,641 188,977 Balance at end of period $ 88,992 $ 84,023
Summary of Remaining Performance Obligation	The remaining performance obligations consisted of the following: (in thousands) June 30, December 31, Current $ 163,304 $ 155,134 Non-current 93,307 95,354 Total $ 256,611 $ 250,488

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 30, 2022
Leases [Abstract]
Schedule of Lease Costs	The Company recorded the following lease costs for the three and six months ended June 30, 2022: (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Lease Cost Capitalized operating lease cost $ 888 $ 1,723 Variable lease cost — 1 Total lease cost $ 888 $ 1,724 (in thousands) Supplemental Cash Flow and Other Information Cash paid for amounts included in measurement of lease liabilities and capitalized operating leases: Operating cash flows $ 1,544 Right-of-use assets obtained in exchange for lease liabilities: Capitalized operating leases $ 803
Schedule of Leases Term and Discount Rate	Lease term and discount rate consisted of the following at June 30, 2022: June 30, 2022 Weighted-average remaining lease term (in years): Capitalized operating leases 6.03 Weighted-average discount rate: Capitalized operating leases 4.2 %
Schedule Of Future Minimum Payments For Operating Leases	The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed consolidated balance sheets as of June 30, 2022. (in thousands) Capitalized Operating Lease 2022, excluding the six months ended June 30, 2022 $ 1,608 2023 1,898 2024 2,353 2025 2,147 2026 2,071 Thereafter 4,488 $ 14,565 Imputed interest 1,744 Lease liability balance at June 30, 2022 $ 12,821
Schedule of Maturities of Lease Liabilities	Future aggregate minimum annual lease payments as of December 31, 2021 reported in our 2021 Form 10-K under the previous lease accounting standard were as follows: (in thousands) Operating Lease 2022 $ 3,120 2023 1,895 2024 2,282 2025 2,174 2026 2,165 Thereafter 4,805 $ 16,441

Short-term Investments (Tables)

Short-term Investments (Tables)	6 Months Ended
Short-term Investments (Tables)	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of short-term investments	Short-term investments classified as available-for-sale consisted of the following: June 30, 2022 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 60,233 $ — $ ( 339 ) $ 59,894 Commercial paper 58,434 — ( 112 ) 58,322 Total short-term investments $ 118,667 $ — $ ( 451 ) $ 118,216

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
Accounts Receivable (Tables)	Jun. 30, 2022
Receivables [Abstract]
Schedule of Accounts Receivable	Accounts receivable consisted of the following: (in thousands) June 30, December 31, Accounts receivable $ 31,839 $ 44,303 Unbilled receivable 1,080 430 32,919 44,733 Less: allowance for doubtful accounts ( 1,185 ) ( 1,397 ) Accounts receivable, net $ 31,734 $ 43,336

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: (in thousands) June 30, December 31, Computers and software $ 5,306 $ 4,744 Furniture and equipment 1,653 1,580 Leasehold improvements 2,798 3,348 9,757 9,672 Less: accumulated depreciation and amortization ( 4,997 ) ( 4,603 ) Property and equipment, net $ 4,760 $ 5,069

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
Goodwill and Intangible Assets (Tables)	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The carrying amounts of goodwill and intangible assets, as of June 30, 2022 and December 31, 2021, consist of the following: June 30, 2022 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 409,430 $ ( 110,696 ) $ 298,734 Developed technologies 57,200 ( 21,453 ) 35,747 Tradenames 36,000 ( 6,096 ) 29,904 Database 46,580 ( 38,769 ) 7,811 Total finite-lived intangible assets 549,210 ( 177,014 ) 372,196 Goodwill 1,322,959 — 1,322,959 Total goodwill and Intangible assets $ 1,872,169 $ ( 177,014 ) $ 1,695,155 December 31, 2021 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 370,030 $ ( 92,942 ) $ 277,088 Developed technologies 51,100 ( 17,475 ) 33,625 Tradenames 35,500 ( 5,034 ) 30,466 Database 43,080 ( 31,789 ) 11,291 Total finite-lived intangible assets 499,710 ( 147,240 ) 352,470 Goodwill 1,261,444 — 1,261,444 Total goodwill and Intangible assets $ 1,761,154 $ ( 147,240 ) $ 1,613,914
Schedule of Future Amortization Expense	Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2022, excluding the six months ended June 30, 2022 $ 25,520 2023 48,216 2024 45,369 2025 41,419 2026 34,878 Thereafter 176,794 Total $ 372,196

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	6 Months Ended
Derivative Instruments and Hedging Activities (Tables)	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of the Interest Rate Swap	The fair values of the interest rate swaps and their respective locations in our condensed consolidated balance sheets at June 30, 2022 were as follows: (in thousands) Description Balance Sheet Location June 30, 2022 Short-term derivative asset Prepaid expenses and other current assets $ 1,453 Long-term derivative asset Other assets 1,887

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
Long-term Debt (Tables)	Jun. 30, 2022
Long-Term Debt, Unclassified [Abstract]
Schedule of Long-term Debt	Long-term debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively: June 30, 2022 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 269,844 $ ( 2,323 ) $ 267,521 Less: current portion of long-term debt 6,875 Long-term debt $ 260,646 December 31, 2021 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 273,282 $ ( 2,599 ) $ 270,683 Less: current portion of long-term debt 6,875 Long-term debt $ 263,808

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs	The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) June 30, December 31, Balance at beginning of period $ 7,500 $ 5,236 Additions 1,000 — Net change in fair value and other adjustments — 3,764 Payments ( 7,500 ) ( 1,500 ) Balance at end of period $ 1,000 $ 7,500
Schedule of Fair Value of Additional Assets and Liabilities Measured at Fair Value on Recurring Basis	At June 30, 2022, additional assets and liabilities measured at fair value on a recurring basis were as follows: (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 432 $ 432 $ — $ — Commercial paper (maturities less than 90 days) 7,990 — 7,990 — Short-term investments: U.S. Treasuries 59,894 — 59,894 — Commercial paper 58,322 — 58,322 — Prepaid expenses and other current assets: Interest rate swap contracts 1,453 — 1,453 — Other Assets: Interest rate swap contracts 1,887 — 1,887 — Liabilities: Other long-term liabilities: Contingent consideration 1,000 — — 1,000

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Jun. 30, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) June 30, December 31, Payroll and payroll-related $ 7,403 $ 10,311 Contingent consideration, current — 7,500 Sales, franchise and other taxes 3,133 1,785 Other 4,146 3,062 Accrued expenses and other current liabilities $ 14,682 $ 22,658

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
Accumulated Other Comprehensive Loss (Tables)	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Summary of Changes in Accumulated Balances in Other Comprehensive Loss	The following table summarize the changes in accumulated balances of other comprehensive loss for the three and six months ended June 30, 2022 and 2021, respectively. Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 (in thousands) Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 1,049 $ ( 197 ) $ 66 $ 918 $ — $ — $ 62 $ 62 Other comprehensive income (loss) before reclassifications 825 ( 93 ) 68 800 1,874 ( 290 ) 72 1,656 Amounts reclassified from AOCI 276 — — 276 276 — — 276 Ending balance at June 30, 2022 $ 2,150 $ ( 290 ) $ 134 $ 1,994 $ 2,150 $ ( 290 ) $ 134 $ 1,994 Three months ended June 30, 2021 Six months ended June 30, 2021 (in thousands) Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Unrealized Gains on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ — $ — $ 32 $ 32 $ — $ — $ ( 131 ) $ ( 131 ) Other comprehensive income (loss) — — ( 19 ) ( 19 ) — — 144 144 Ending balance at June 30, 2021 $ – – $ – – $ 13 $ 13 $ – – $ – – $ 13 $ 13

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
Equity-Based Compensation (Tables)	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Equity Based Compensation Expense Recognized	A summary of the expense by line item in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively, is provided in the following table. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 230 $ 16 $ 462 $ 31 Sales and marketing 5,056 139 8,802 241 Product development 1,841 78 3,130 154 General and administrative 1,878 1,382 3,483 1,595 Total compensation expense $ 9,005 $ 1,615 $ 15,877 $ 2,021
IPO [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Company’s Unvested Time-Based and Performance-Based Unit Activity	The following table summarizes the Company’s unvested unit activity. Time-Based Weighted Non-Vested Average Grant Units Date Fair Value Unvested at December 31, 2021 2,756,406 $ 2.02 Granted — — Vested ( 150,862 ) 1.58 Forfeited ( 56,356 ) 1.75 Unvested at June 30, 2022 2,549,188 $ 2.06
Time Based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Company’s Unvested Time-Based and Performance-Based Unit Activity	The following table summarizes the Company’s unvested time-based RSU activity for the six months ended June 30, 2022: Time-Based RSUs Weighted Restricted Average Grant Stock Units Date Fair Value Unvested at December 31, 2021 1,935,899 $ 32.59 Granted 1,659,216 22.74 Vested ( 11,729 ) 17.11 Forfeited ( 100,857 ) 26.65 Unvested at June 30, 2022 3,482,529 $ 28.12
Performance-Based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Company’s Unvested Time-Based and Performance-Based Unit Activity	The following table summarizes the Company’s unvested PSU activity for the six months ended June 30, 2022. Performance-Based PSUs Weighted Restricted Average Grant Stock Units Date Fair Value Unvested at December 31, 2021 164,351 $ 27.00 Granted 125,000 54.25 Vested — — Forfeited ( 9,259 ) 27.00 Unvested at June 30, 2022 280,092 $ 39.16

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
Loss Per Share (Tables)	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and six months ended June 30, 2022 . (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Numerator: Net loss $ ( 9,579 ) $ ( 22,636 ) Less: Net loss attributable to noncontrolling interests ( 4,429 ) ( 8,862 ) Net loss attributable to Definitive Healthcare Corp. $ ( 5,150 ) $ ( 13,774 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and six months ended June 30, 2022 (per share amounts unaudited). (in thousands, except number of shares and per share amounts) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 5,150 ) $ ( 13,774 ) Weighted average number of shares of Class A Common Stock outstanding 99,203,697 98,186,909 Net loss per share, basic and diluted $ ( 0.05 ) $ ( 0.14 )
Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2022 Definitive OpCo Units (vested and unvested) 54,745,380 Restricted Stock Units 3,762,621

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	6 Months Ended
Segment and Geographic Data (Tables)	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Revenue by Geographic Areas	Revenues by geographic area presented based upon the location of the customer are as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 United States $ 52,028 $ 38,489 $ 99,608 $ 74,186 Rest of world 2,520 1,332 5,064 2,571 Total revenues $ 54,548 $ 39,821 $ 104,672 $ 76,757
Schedule of Long-Lived Assets by Geographic Areas	Long-lived assets by geographical region are based on the location of the legal entity that owns the assets. Long-lived assets by geographic area presented based upon the location of the assets are as follows: (in thousands) June 30, December 31, United States $ 4,272 $ 4,705 Rest of world 488 364 Total long-lived assets $ 4,760 $ 5,069

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended
	Nov. 22, 2021	Sep. 17, 2021	Jun. 30, 2022
Entity Incorporation, Date of Incorporation			May 05, 2021
Acquisition of Limited Liability Company (LLC)		14,222,222
Purchase Of Limited Liability Company (LLC) Unit		1,169,378
Noninterest Expense Offering Cost			$ 11.4
Fees and Expense			11.4
Common Class A [Member]
Issuance of Class A common stock in IPO net of costs, Share		17,888,888
Share Price		$ 27
Proceeds from Issuance Initial Public Offering		$ 452.8
Repurchase of share, Shares		2,497,288
Follow-On Offering [Member] \| Common Class A [Member]
Issuance of Class A common stock in IPO net of costs, Share	11,000,000
Share Price	$ 36
Proceeds from Issuance Initial Public Offering	$ 382.1
IPO [Member]
Proceeds to repay outstanding debt			$ 199.6
Definitive OpCo [Member] \| Follow-On Offering [Member]
Acquisition of Limited Liability Company (LLC)	7,000,000
Purchase Of Limited Liability Company (LLC) Unit	1,766,762
Noninterest Expense Offering Cost	$ 1.6
Fees and Expense	$ 1.6
Definitive OpCo [Member] \| Follow-On Offering [Member] \| Common Class A [Member]
Repurchase of share, Shares	2,233,238

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Additional Information) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Summary Of Significant Accounting Policies Additional Information Details [Line Items]
Contract liabilities	$ 88,992		$ 84,023	$ 61,200
Operating Lease, Liability	12,821
Operating lease right of use asset	$ 10,552		$ 0
AW acquisition
Disclosure Summary Of Significant Accounting Policies Additional Information Details [Line Items]
Contract liabilities		$ 3,400
ASU 2016-02 [Member]
Disclosure Summary Of Significant Accounting Policies Additional Information Details [Line Items]
Operating lease term of contract	12 months
Operating Lease, Liability	$ 14,000
Operating lease right of use asset	$ 12,700

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) $ in Thousands			6 Months Ended	12 Months Ended
	Feb. 18, 2022 USD ($)	Dec. 22, 2021 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Investment		$ 40,000
Purchase option ownership percentage		65%
Purchase of Ownership percentage	65
Cash consideration paid at closing	$ 58,600		$ 58,645
Purchase price			99,443
Working capital adjustments	200		(202)
Contingent consideration	5,000		1,000
Initial value of contingent consideration			1,000
Fair value of the contingent consideration	1,000
Initial cash investment in December 2021	40,000			$ 40,000
Escrow deposit	10,000
Purchase price consideration	65,000
Developed software
Other assets	6,100
Analytical Wizards Acquisition [Member]
Purchase price	99,400
Trade Names [Member]
Other assets	500
Customer Relationships [Member]
Other assets	39,400
Goodwill [Member]
Other assets	61,500
Series Of Individually Immaterial Business Acquisitions Member
Potential payouts range, Low	0
Potential payouts range, High	5,000
AW acquisition
Fair value of the contingent consideration	$ 1,000
Weighted average amortization period	20 years
Business combination, Acquisition related costs			$ 1,200
Date of acquisition			Feb. 18, 2022
AW acquisition \| Developed software
Other assets	$ 6,100
Weighted average amortization period	6 years
AW acquisition \| Trade Names [Member]
Weighted average amortization period	5 years
AW acquisition \| Trademarks Member
Other assets	$ 500
Customer relationships	5 years
AW acquisition \| Customer Relationships [Member]
Other assets	$ 39,400
Weighted average amortization period	20 years
Call Option [Member]
Stock issued during period value stock options exercised		$ 65,000
Option indexed to issuers equity settlement alternatives cash at fair value		$ 7,300
Series B Preferred Stock [Member]
Preferred stock convertible conversion ratio		0.35
Option indexed to issuers equity settlement alternatives cash at fair value		$ 32,700
Series B Preferred Stock [Member] \| Purchase Option [Member]
Option indexed to issuers equity settlement alternatives cash at fair value		$ 40,000

Acquisitions - Summary of Trans

Acquisitions - Summary of Transaction Transferred (Details) - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
	Feb. 18, 2022	Jun. 30, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Initial cash investment in December 2021	$ 40,000		$ 40,000
Cash consideration paid at closing	58,600	$ 58,645
Working capital adjustments	200	(202)
Contingent consideration	$ 5,000	1,000
Purchase price		$ 99,443

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired (Details) - AW acquisition $ in Thousands	Feb. 18, 2022 USD ($)
Cash	$ 2,146
Accounts receivable	3,525
Prepaid expenses and other current assets	640
Property and equipment	134
Intangible assets	46,000
Right-of-use asset, operating leases	832
Other assets	703
Accounts payable and accrued expenses	(821)
Deferred revenue	(3,365)
Right-of-use liability, operating leases	(832)
Deferred taxes	(10,135)
Other liabilities	(900)
Total assets acquired and liabilities assumed	37,927
Goodwill	61,516
Purchase price	$ 99,443

Acquisitions - Schedule of Busi

Acquisitions - Schedule of Business Acquisition, Pro Forma Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Business Combinations [Abstract]
Revenue	$ 106,149	$ 81,765
Net loss	$ (22,136)	$ (26,582)

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 54,548	$ 39,821	$ 104,672	$ 76,757
Platform Subscriptions [Member]
Disaggregation Of Revenue [Line Items]
Revenue	53,211	39,400	102,980	75,765
Professional Services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,337	$ 421	$ 1,692	$ 992

Revenue - Summary of Receivable

Revenue - Summary of Receivables, Deferred Contract Costs and Contract Liabilities from Contract with Customers (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Accounts receivable, net	$ 31,734	$ 43,336
Deferred contract costs, current portion	8,469	6,880
Deferred contract costs, long-term	12,933	11,667
Deferred revenues	$ 88,992	$ 84,023

Revenue - Summary of Deferred C

Revenue - Summary of Deferred Contract Costs (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Additional amounts deferred	$ 109,641		$ 188,977
Deferred contract costs, net of current portion	12,933		11,667
Deferred contract costs	(6,846)	$ (6,042)
Deferred Contract Costs [Member]
Disaggregation of Revenue [Line Items]
Balance at beginning of period	18,547	$ 8,899	8,899
Costs amortized	(3,991)		(4,792)
Additional amounts deferred	6,846		14,440
Balance at end of period	21,402		18,547
Deferred contract costs, net of current portion	8,469		6,880
Non-current	12,933		11,667
Deferred contract costs	$ 21,402		$ 18,547

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Balances (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Balance at beginning of period	$ 84,023	$ 61,200
Revenue recognized	(104,672)	(166,154)
Additional amounts deferred	109,641	188,977
Balance at end of period	$ 88,992	$ 84,023

Revenue (Additional Information

Revenue (Additional Information) (Details)	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Percentage of revenue expected to recognize	64%

Revenue - Summary of Remaining

Revenue - Summary of Remaining Performance Obligation (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Current	$ 163,304	$ 155,134
Noncurrent	93,307	95,354
Total	$ 256,611	$ 250,488

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Lessee, Lease, Description [Line Items]
Finance lease liability	$ 0			$ 0
Option to extend lease term		the Company gave notice of its intent to extend one of its office lease facilities for an additional five-year period and the extension was accounted for as a lease modification under ASC 842.
Lease existence of option to extend		true
Additional lease term period		5 years
Operating lease liability to be paid	14,565			14,565
Product Development [Member]
Lessee, Lease, Description [Line Items]
Rental Expenses	700		$ 700	1,500	$ 1,300
Office Space Facilities
Lessee, Lease, Description [Line Items]
Operating lease liability to be paid	6,000	$ 6,000		6,000
Impairment charge	$ 200			$ 700
Office Space Facilities \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Operating lease term of contract	9 years			9 years
Operating lease, renewal term	10 years			10 years
Office Space Facilities \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Operating lease term of contract	1 year			1 year
Operating lease, renewal term	5 years			5 years

Leases - Schedule of lease cost

Leases - Schedule of lease costs (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Lease, Cost [Abstract]
Capitalized operating lease cost	$ 888	$ 1,723
Variable Lease, Cost	0	1
Total lease cost	$ 888	$ 1,724

Leases - Supplemental cash flow

Leases - Supplemental cash flow information related to leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Cash paid for amounts included in the measurement of lease liabilities and capitalized operating leases.
Operating cash flows	$ 1,544
Right Of Use Assets Obtained In Exchange For New Lease Liabilities Abstract
Capitalized operating leases	$ 803

Leases - Schedule of lease term

Leases - Schedule of lease term and discount rate (Details)	Jun. 30, 2022
Weighted-Average Remaining Lease Term Abstract
Capitalized operating leases	6 years 10 days
Weighted-Average Discount Rate Abstract
Capitalized operating leases	4.20%

Leases - Schedule of operating

Leases - Schedule of operating lease liabilities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Leases [Abstract]
2022, excluding the six months ended June 30, 2022	$ 1,608
2023	1,898
2024	2,353
2025	2,147
2026	2,071
Thereafter	4,488
Total undiscounted future minimum lease payments	14,565
Imputed interest	(1,744)
Operating lease liability	$ 12,821

Leases - Schedule of maturities

Leases - Schedule of maturities of lease liabilities (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 3,120
2023	1,895
2024	2,282
2025	2,174
2026	2,165
Thereafter	4,805
Total	$ 16,441

Short-term Investments - Schedu

Short-term Investments - Schedule of short-term Investments (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 118,667
Gross unrealized gains	0
Gross unrealized losses	(451)
Fair Value	118,216
Commercial Paper [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	58,434
Gross unrealized gains	0
Gross unrealized losses	(112)
Fair Value	58,322
U.S. Treasuries [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	60,233
Gross unrealized gains	0
Gross unrealized losses	(339)
Fair Value	$ 59,894

Accounts Receivable - Schedule

Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable	$ 31,839	$ 44,303
Unbilled receivable	1,080	430
Accounts receivable, gross	32,919	44,733
Less: allowance for doubtful accounts	(1,185)	(1,397)
Accounts receivable, net	$ 31,734	$ 43,336

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 9,757	$ 9,672
Less: accumulated depreciation and amortization	(4,997)	(4,603)
Property and equipment, net	4,760	5,069
Computers and Software [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	5,306	4,744
Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	1,653	1,580
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,798	$ 3,348

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 10,194	$ 9,608	$ 20,068	$ 19,054
Impairment charges	1,000		1,000
Fully depreciated property and equipment, in use	1,000		1,000
Computer Equipment
Property Plant And Equipment [Line Items]
Depreciation and amortization	200		200
Right-of-use assets
Property Plant And Equipment [Line Items]
Impairment charges	900		900
Leasehold Improvements
Property Plant And Equipment [Line Items]
Impairment charges	100		100
Property And Equipment [Member]
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 800	$ 400	$ 1,300	$ 700

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 549,210	$ 499,710
Accumulated Amortization	(177,014)	(147,240)
Net Carrying Amount	372,196	352,470
Goodwill [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,322,959	1,261,444
Accumulated Amortization	0	0
Net Carrying Amount	1,322,959	1,261,444
Goodwill And Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,872,169	1,761,154
Accumulated Amortization	(177,014)	(147,240)
Net Carrying Amount	1,695,155	1,613,914
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	409,430	370,030
Accumulated Amortization	(110,696)	(92,942)
Net Carrying Amount	298,734	277,088
Developed Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	57,200	51,100
Accumulated Amortization	(21,453)	(17,475)
Net Carrying Amount	35,747	33,625
Trade Names [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	36,000	35,500
Accumulated Amortization	(6,096)	(5,034)
Net Carrying Amount	29,904	30,466
Databases [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	46,580	43,080
Accumulated Amortization	(38,769)	(31,789)
Net Carrying Amount	$ 7,811	$ 11,291

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Segment	Jun. 30, 2021 USD ($)
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 29,774,000	$ 28,853,000
Amortization	$ 5,580,000	$ 5,299,000	$ 10,958,000	10,540,000
Number of Reporting Units \| Segment			1
Impairment of goodwill			$ 0	0
AW acquisition
Finite Lived Intangible Assets [Line Items]
Goodwill, Period Increase (Decrease)			61,500,000
Finite Lived Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	15,100,000	14,500,000	29,800,000	28,800,000
Amortization	$ 5,600,000	$ 5,300,000	$ 11,000,000	$ 10,500,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022, excluding the three months ended March 31, 2022	$ 25,520
2023	48,216
2024	45,369
2025	41,419
2026	34,878
Thereafter	176,794
Net Carrying Amount	$ 372,196	$ 352,470

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)	Mar. 31, 2022 Segment	Dec. 31, 2021 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Net pre-tax gains	$ 0		$ 0
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Number of Instruments Held \| Segment		2
Notional amount	$ 67,500,000
Maturity date	Mar. 31, 2025
Net pre-tax gains	$ 1,500,000
Interest Rate Swaps [Member] \| Goldman Sachs Bank USA [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	2.0135%
Interest Rate Swaps [Member] \| Bank of America N.A [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	2.012%

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Summary of Fair Values of the Interest Rate Swap (Details) - Interest Rate Swap [Member] $ in Thousands	Jun. 30, 2022 USD ($)
Other Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Long-term derivative asset	$ 1,887
Accrued Expenses and Other Current Liabilities [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Short-term derivative asset	$ 1,453

Long-term Debt - Schedule of Lo

Long-term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Less: current portion of long-term debt	$ 6,875	$ 6,875
Long-term debt	260,646	263,808
2021 Term Loan [Member]
Debt Instrument [Line Items]
Principal	269,844	273,282
Unamortized debt issuance costs / financing costs	(2,323)	(2,599)
Total debt, net	$ 267,521	$ 270,683

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details) - USD ($) $ in Thousands		6 Months Ended
	Sep. 17, 2021	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Frequency of payment		The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the "Initial Amortization Date"), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year and fifth year after the Initial Amortization Date.
Financing costs		$ 3,500
2021 Term Loan [Member]
Debt Instrument [Line Items]
Repayment of debt		3,400
Outstanding principal balance		269,844	$ 273,282
Balloon payment		220,000
Financing costs		2,800
Unamortized debt issuance costs / financing costs		$ (2,323)	$ (2,599)
2021 Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Maturity date	Sep. 17, 2026
Line of credit	$ 75,000
Interest rate		3.92%
Financing costs		$ 800
Unamortized debt issuance costs / financing costs		$ (600)
2021 Revolving Line of Credit [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.25%
2021 Revolving Line of Credit [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.30%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Business combination, Contingent consideration, Liability	$ 1
Office Relocation [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset Impairment Charges	1
Operating Lease Right Of Use Asset [Member] \| Office Relocation [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset Impairment Charges	0.9
Leasehold Improvements \| Office Relocation [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset Impairment Charges	$ 0.1

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs (Details) - Fair Value, Inputs, Level 3 - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at beginning of period	$ 7,500	$ 5,236
Additions	1,000	0
Net change in fair value and other adjustments	0	3,764
Payments	(7,500)	(1,500)
Balance at end of period	$ 1,000	$ 7,500

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Additional Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ (1,000)	$ 0
Recurring [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	59,894
Recurring [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	58,322
Recurring [Member] \| Interest Rate Swap [Member] \| Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,453
Recurring [Member] \| Interest Rate Swap [Member] \| Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,887
Recurring [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,000
Recurring [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	432
Recurring [Member] \| Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	7,990
Level 1 [Member] \| Recurring [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 1 [Member] \| Recurring [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 1 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 1 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 1 [Member] \| Recurring [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Level 1 [Member] \| Recurring [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	432
Level 1 [Member] \| Recurring [Member] \| Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 2 [Member] \| Recurring [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	59,894
Level 2 [Member] \| Recurring [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	58,322
Level 2 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,453
Level 2 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,887
Level 2 [Member] \| Recurring [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Level 2 [Member] \| Recurring [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 2 [Member] \| Recurring [Member] \| Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	7,990
Level 3 [Member] \| Recurring [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 3 [Member] \| Recurring [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 3 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 3 [Member] \| Recurring [Member] \| Interest Rate Swap [Member] \| Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 3 [Member] \| Recurring [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,000
Level 3 [Member] \| Recurring [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 3 [Member] \| Recurring [Member] \| Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 0

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses And Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and payroll-related	$ 7,403	$ 10,311
Contingent consideration, current	0	7,500
Sales, franchise and other taxes	3,133	1,785
Other	4,146	3,062
Accrued expenses and other current liabilities	$ 14,682	$ 22,658

Stockholders' Equity and Member

Stockholders' Equity and Members' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Class Of Stock [Line Items]
Members' contributions			$ 5,500
Equity-based compensation	$ 9,005	$ 6,872	$ 1,615	$ 406

Noncontrolling Interest - Addit

Noncontrolling Interest - Additional Information (Details) - shares	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	100,484,715	97,030,095
Definitive OpCo [Member]
Noncontrolling Interest [Line Items]
Number of shares held	100,484,715
Ownership interest (as a percent)	65.80%
Noncontrolling interest	34.20%
Definitive OpCo [Member] \| Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	3,442,891
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,729
Issuance of common stock shares	11,729

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Balances in Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Unrealized Gains on Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 1,049	$ 0	$ 0	$ 0
Other comprehensive income (loss)		0		0
Other comprehensive income (loss) before reclassifications	825		1,874
Amounts reclassified from AOCI	276		276
Ending Balance	2,150	0	2,150	0
Unrealized Loss on Investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(197)	0	0	0
Other comprehensive income (loss)		0		0
Other comprehensive income (loss) before reclassifications	(93)		(290)
Amounts reclassified from AOCI	0		0
Ending Balance	(290)	0	(290)	0
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	66	32	62	(131)
Other comprehensive income (loss)		(19)		144
Other comprehensive income (loss) before reclassifications	68		72
Amounts reclassified from AOCI	0		0
Ending Balance	134	13	134	13
AOCI Attributable to Parent [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	918	32	62	(131)
Other comprehensive income (loss)		(19)		144
Other comprehensive income (loss) before reclassifications	800		1,656
Amounts reclassified from AOCI	276		276
Ending Balance	$ 1,994	$ 13	$ 1,994	$ 13

Equity-Based Compensation Expen

Equity-Based Compensation Expense - Summary of Equity Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9,005	$ 1,615	$ 15,877	$ 2,021
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	230	16	462	31
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,056	139	8,802	241
Product Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,841	78	3,130	154
General And Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,878	$ 1,382	$ 3,483	$ 1,595

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 9,005	$ 1,615	$ 15,877	$ 2,021
Time Based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	7,000		12,100
Unrecognized expense related to unit-based compensation	81,600		$ 81,600
Weighted-average period over which cost not yet recognized is expected to be recognized			2 years 10 months 24 days
Performance Based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	500		$ 700
Unrecognized expense related to unit-based compensation	8,100		$ 8,100
Weighted-average period over which cost not yet recognized is expected to be recognized			2 years
Performance Based RSUs [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting percentage			300%
Performance Based RSUs [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting percentage			0%
Time Based Unit
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	1,500	600	$ 3,000	1,000
Unrecognized expense related to unit-based compensation	12,100		$ 12,100
Weighted-average period over which cost not yet recognized is expected to be recognized			2 years 1 month 6 days
General And Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,878	$ 1,382	$ 3,483	$ 1,595
2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized	3,774,350		3,774,350
2021 Equity Incentive Plan \| Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized	5,214,689		5,214,689
IPO \| 2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issue price per share	$ 27		$ 27

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Company's Unvested Time-Based and Performance-Based Unit Activity (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Time-Based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2021 \| shares	1,935,899
Granted \| shares	1,659,216
Vested \| shares	(11,729)
Forfeited \| shares	(100,857)
Non-vested at June 30, 2022 \| shares	3,482,529
Non vested weighted average grant date fair value \| $ / shares	$ 32.59
Non vested weighted average grant date fair value, Granted \| $ / shares	22.74
Non vested weighted average grant date fair value, vested \| $ / shares	17.11
Non vested weighted average grant date fair value, forfeited \| $ / shares	26.65
Non vested weighted average grant date fair value \| $ / shares	$ 28.12
Performance-Based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2021 \| shares	164,351
Granted \| shares	125,000
Vested \| shares	0
Forfeited \| shares	(9,259)
Non-vested at June 30, 2022 \| shares	280,092
Non vested weighted average grant date fair value \| $ / shares	$ 27
Non vested weighted average grant date fair value, Granted \| $ / shares	54.25
Non vested weighted average grant date fair value, vested \| $ / shares	0
Non vested weighted average grant date fair value, forfeited \| $ / shares	27
Non vested weighted average grant date fair value \| $ / shares	$ 39.16
Time Based Unit
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2021 \| shares	2,756,406
Granted \| shares	0
Vested \| shares	(150,862)
Forfeited \| shares	(56,356)
Non-vested at June 30, 2022 \| shares	2,549,188
Non vested weighted average grant date fair value \| $ / shares	$ 2.02
Non vested weighted average grant date fair value, Granted \| $ / shares	0
Non vested weighted average grant date fair value, vested \| $ / shares	1.58
Non vested weighted average grant date fair value, forfeited \| $ / shares	1.75
Non vested weighted average grant date fair value \| $ / shares	$ 2.06

Retirement Plans - Additional I

Retirement Plans - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Retirement Benefits [Abstract]
Employer matching contributions, amount	$ 0.8	$ 0.5	$ 1.9	$ 1.2

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes - Additional Information (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Tax Credit Carryforward [Table]
Unrecognized tax benefits	$ 0		$ 0		$ 0
Effective tax rate	2.20%	0%	0.60%	0%
Deferred Tax Liability Due to Acquisition	$ 100,000		$ 100,000
Deferred tax liability	85,600,000		85,600,000
Tax receivable agreement liability			$ 155,900,000
Tax receivable agreement realized tax benefits payable to related parties percent			85%
Tax Receivable Agreement Benefit percentage			15%
Tax Receivable Agreement Realized Tax Benefits Payable To Related Parties			$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
TRA Remeasurement Gain	$ 3,400,000		$ 3,100,000

Loss Per Share - Schedule of Ne

Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net loss		$ (9,579)	$ (13,057)	$ (15,039)	$ (22,636)	$ (25,527)
Less: Net loss attributable to noncontrolling interests		(4,429)		0	(8,862)	0
Net loss attributable to Definitive Healthcare Corp.		(5,150)		0	(13,774)	0
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.		$ (5,150)		$ 0	$ (13,774)	$ 0
Weighted average number of shares of Class A outstanding	[1]	99,203,697			98,186,909
Net loss per share, basic	[1]	$ (0.05)			$ (0.14)
Net loss per share, diluted	[1]	$ (0.05)			$ (0.14)
Common Class A [Member]
Net loss		$ (9,579)			$ (22,636)
Less: Net loss attributable to noncontrolling interests		(4,429)			(8,862)
Net loss attributable to Definitive Healthcare Corp.		(5,150)			(13,774)
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.		$ (5,150)			$ (13,774)
Weighted average number of shares of Class A outstanding		99,203,697			98,186,909
Net loss per share, basic		$ (0.05)			$ 0.14
Net loss per share, diluted		$ (0.05)			$ 0.14

[1] (1) Basic and diluted net loss per share of Class A Common Stock is applicable only for the periods beginning from September 15, 2021, which is the period following the IPO and related Reorganization Transactions. See Note 19 for the number of shares used in the computation of net loss per share of Class A Common Stock and the basis for the computation of net loss per share.

Loss Per Share - Schedule of Di

Loss Per Share - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)	6 Months Ended
	Jun. 30, 2022 shares
Vested and Unvested Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount	54,745,380
Restricted Stock Unit [Member]
Antidilutive securities excluded from computation of earnings per share, amount	3,762,621

Segment and Geographic Data - S

Segment and Geographic Data - Schedule of Revenue by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 54,548	$ 39,821	$ 104,672	$ 76,757
United States [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	52,028	38,489	99,608	74,186
Rest of World [Member]
Entity Wide Revenue Major Customer [Line Items]
Revenue	$ 2,520	$ 1,332	$ 5,064	$ 2,571

Segment and Geographic Data -_2

Segment and Geographic Data - Schedule of Long-Lived Assets by Geographic Areas) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Total long-lived assets	$ 4,760	$ 5,069
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total long-lived assets	4,272	4,705
Rest of World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total long-lived assets	$ 488	$ 364

Related parties - Additional In

Related parties - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Revenue from related parties	$ 200	$ 300	$ 400	$ 400
Receivable, related parties	$ 0		$ 0		$ 600